{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {
    "collapsed": true,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:15.553119800Z",
     "start_time": "2023-06-14T06:42:15.532507700Z"
    }
   },
   "outputs": [],
   "source": [
    "from common import *"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "outputs": [],
   "source": [
    "TEMPLATE = \"\"\"\n",
    "    请根据以下context，回答：{query_str}\n",
    "    reply in {language_str}\n",
    "    ---------context\n",
    "    {context_str}\n",
    "    ---------\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:16.812191600Z",
     "start_time": "2023-06-14T06:42:16.796767300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "outputs": [],
   "source": [
    "def chat(context,question,lang=\"简体中文\"):\n",
    "    query = TEMPLATE.replace(\"{context_str}\",context).replace(\"{query_str}\",question).replace(\"{language_str}\",lang)\n",
    "    gpt_model = \"gpt-3.5-turbo-16k\"\n",
    "    prompt = prompt_templates.FIELD_EXTRACTOR_TEMPLATE\n",
    "    result = get_data(query, prompt=prompt, model=gpt_model)\n",
    "    print(f\"+++++++++++++++++++++++++\\n{result}\")\n",
    "    # return result\n"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:16.906861400Z",
     "start_time": "2023-06-14T06:42:16.891014300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "outputs": [],
   "source": [
    "cqq_txt = \"\"\"\n",
    "    临床研究clinical trials，NCT05572983\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":22633,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT05572983\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
    "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"September 2022\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"September 1, 2022\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"September 1, 2024\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"September 1, 2026\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"September 30, 2022\",\n",
    "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"October 10, 2022\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"October 10, 2022\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"N/A\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"47\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: Chidamide combined with CHOP\",\n",
    "                    \"Drug: Chidamide\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
    "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Chidamide in Combination With CHOP\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Induction treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Chidamide\",\n",
    "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Chidamide in Combination With CHOP\"\n",
    "                  ]\n",
    "                },\n",
    "                \"InterventionOtherNameList\":{\n",
    "                  \"InterventionOtherName\":[\n",
    "                    \"Maintenance treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
    "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
    "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
    "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nAge ≥18 years old and ≤75 years old, male and female;\\nPeripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\\nNever received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\\nAutologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\\nThere must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\\nEastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\\nExpected survival ≥ 3 months;\\n\\nThe following required baseline laboratory data:\\n\\n.White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\\n.Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\\n.Renal function：creatinine, Cr≤1.5×ULN\\n.Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\\n.Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\\nSubjects fully understand and voluntarily participate in this study and sign informed consent\\n\\nExclusion Criteria:\\n\\nA history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\\nPatients with significant vital organ dysfunction;\\nPatients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\\nPatients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\\nPatients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\\nSubjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\\nWith active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\\nPatients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\\nPatients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\\nLong-term unhealed wounds or incomplete healing fractures;\\nReceive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\\nPregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\\nPatients with mental illness or who cannot obtain informed consent;\\nThere is active infection, except for tumor-related B symptoms and fever;\\nCardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\\nIneligibility to participate in the study was determined by the investigator.\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"75 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Study Director\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Guangdong\",\n",
    "                \"LocationZip\":\"510000\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000008223\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000016399\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000016411\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008232\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008206\",\n",
    "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007160\",\n",
    "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007154\",\n",
    "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008228\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M10372\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M17981\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
    "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M17985\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
    "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10377\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10355\",\n",
    "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9358\",\n",
    "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9352\",\n",
    "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10374\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T3543\",\n",
    "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T4496\",\n",
    "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
    "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
    "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Intervention Browse Module\":{\n",
    "          \"Intervention Browse Leaf List\":{\n",
    "            \"Intervention Browse Leaf\":[\n",
    "              {\n",
    "                \"Intervention Browse LeafId\":\"M5879\",\n",
    "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M17106\",\n",
    "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M6644\",\n",
    "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M13273\",\n",
    "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M16647\",\n",
    "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Intervention Browse LeafId\":\"M227311\",\n",
    "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Branch List\":{\n",
    "            \"Intervention Browse Branch\":[\n",
    "              {\n",
    "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
    "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
    "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
    "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
    "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT04996758\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":66911,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT04996758\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"B2021-055\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
    "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"March 2022\",\n",
    "          \"Overall Status\":\"Recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"August 1, 2021\",\n",
    "            \"Start DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"August 2023\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"August 2028\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"August 5, 2021\",\n",
    "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"August 9, 2021\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"March 24, 2022\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Nasopharyngeal Carcinoma\",\n",
    "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"N/A\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"39\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: Toripalimab and Anlotinib\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
    "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
    "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
    "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
    "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
    "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              },{\n",
    "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
    "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed undifferentiated non-keratinizing carcinoma\\nPatients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\\nWithout other malignancy;\\nMale or female, 18-70 years;\\nEastern Cooperative Oncology Group (ECOG) of 0-2;\\nLife expectancy ≥ 3 months;\\nWomen of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\\nAt least one evaluable lesion；\\nLaboratory tests meet the following standards:\\n\\nBlood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\\n\\nNo serious cardiopulmonary dysfunction;\\nThe informed consent has been signed.\\nAbility to comply with test requirements\\n\\nExclusion Criteria:\\n\\nA known allergy to any of the drugs in the study;\\nPregnant or breastfeeding women;\\nParticipated in clinical trials of other drugs within 4 weeks prior to study initiation;\\nPrevious treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\\nRecurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\\nPalliative radiotherapy for symptom control within 28 days before enrollment;\\nImmunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\\nActive autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\\nA history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\\nVaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\\nInvasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\\nA history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\\nAbnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\\nUnstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\\nPatients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\\nPatients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\\nA history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\\nMultiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\\nOveroperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\\nPatients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\\nExacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\\nActive pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\\nDominant jaundice due to abnormal liver function within 7 days;\\nRenal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\\nMinor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\\nMajor surgery within 28 days before enrollment;\\nA potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\\nLong-term unhealed wounds or incomplete fractures;\\nSymptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\\nThe presence of serious or uncontrolled infections;\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"70 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              },{\n",
    "                \"CentralContactName\":\"Qingqing Cai\",\n",
    "                \"CentralContactRole\":\"Contact\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
    "                \"LocationStatus\":\"Recruiting\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationZip\":\"510030\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai\",\n",
    "                      \"LocationContactRole\":\"Contact\",\n",
    "                      \"LocationContactPhone\":\"18565617120\",\n",
    "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000002277\",\n",
    "                \"Condition MeshTerm\":\"Carcinoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000077274\",\n",
    "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000012008\",\n",
    "                \"Condition MeshTerm\":\"Recurrence\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009375\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000020969\",\n",
    "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010335\",\n",
    "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009303\",\n",
    "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010610\",\n",
    "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010039\",\n",
    "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000006258\",\n",
    "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009371\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009302\",\n",
    "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010608\",\n",
    "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009057\",\n",
    "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000010038\",\n",
    "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M4686\",\n",
    "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M14002\",\n",
    "                \"Condition Browse LeafName\":\"Recurrence\",\n",
    "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M1730\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11472\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M21853\",\n",
    "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11406\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12669\",\n",
    "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12114\",\n",
    "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8500\",\n",
    "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11405\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12667\",\n",
    "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11169\",\n",
    "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M12113\",\n",
    "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T4047\",\n",
    "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
    "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
    "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
    "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床研究clinical trials，NCT04797182\n",
    "{\n",
    "  \"Full Study\":{\n",
    "    \"Rank\":82232,\n",
    "    \"Study\":{\n",
    "      \"Protocol Section\":{\n",
    "        \"Identification Module\":{\n",
    "          \"NCT Id\":\"NCT04797182\",\n",
    "          \"Org Study Id Info\":{\n",
    "            \"Org Study Id\":\"B2021-034\"\n",
    "          },\n",
    "          \"Organization\":{\n",
    "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
    "            \"Org Class\":\"OTHER\"\n",
    "          },\n",
    "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
    "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
    "        },\n",
    "        \"Status Module\":{\n",
    "          \"Status Verified Date\":\"March 2021\",\n",
    "          \"Overall Status\":\"Not yet recruiting\",\n",
    "          \"Expanded Access Info\":{\n",
    "            \"Has Expanded Access\":\"No\"\n",
    "          },\n",
    "          \"Start Date Struct\":{\n",
    "            \"Start Date\":\"April 2021\",\n",
    "            \"Start DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Primary Completion Date Struct\":{\n",
    "            \"Primary Completion Date\":\"April 2023\",\n",
    "            \"Primary Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Completion Date Struct\":{\n",
    "            \"Completion Date\":\"July 2023\",\n",
    "            \"Completion DateType\":\"Anticipated\"\n",
    "          },\n",
    "          \"Study First Submit Date\":\"March 11, 2021\",\n",
    "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
    "          \"Study First Post Date Struct\":{\n",
    "            \"Study First Post Date\":\"March 15, 2021\",\n",
    "            \"Study First Post DateType\":\"Actual\"\n",
    "          },\n",
    "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
    "          \"Last Update Post Date Struct\":{\n",
    "            \"Last Update Post Date\":\"March 15, 2021\",\n",
    "            \"Last Update Post DateType\":\"Actual\"\n",
    "          }\n",
    "        },\n",
    "        \"Sponsor Collaborators Module\":{\n",
    "          \"Responsible Party\":{\n",
    "            \"Responsible PartyType\":\"Principal Investigator\",\n",
    "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
    "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
    "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
    "          },\n",
    "          \"Lead Sponsor\":{\n",
    "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
    "            \"Lead SponsorClass\":\"OTHER\"\n",
    "          }\n",
    "        },\n",
    "        \"Oversight Module\":{\n",
    "          \"Is FDA Regulated Drug\":\"No\",\n",
    "          \"Is FDA Regulated Device\":\"No\"\n",
    "        },\n",
    "        \"Description Module\":{\n",
    "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
    "        },\n",
    "        \"Conditions Module\":{\n",
    "          \"Condition List\":{\n",
    "            \"Condition\":[\n",
    "              \"Thrombocytopenia\",\n",
    "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
    "              \"Lymphoma\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Design Module\":{\n",
    "          \"Study Type\":\"Interventional\",\n",
    "          \"PhaseList\":{\n",
    "            \"Phase\":[\n",
    "              \"Phase 2\"\n",
    "            ]\n",
    "          },\n",
    "          \"Design Info\":{\n",
    "            \"DesignAllocation\":\"Randomized\",\n",
    "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
    "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
    "            \"DesignMaskingInfo\":{\n",
    "              \"DesignMasking\":\"None (Open Label)\"\n",
    "            }\n",
    "          },\n",
    "          \"Enrollment Info\":{\n",
    "            \"Enrollment Count\":\"46\",\n",
    "            \"Enrollment Type\":\"Anticipated\"\n",
    "          }\n",
    "        },\n",
    "        \"Arms Interventions Module\":{\n",
    "          \"Arm Group List\":{\n",
    "            \"Arm Group\":[\n",
    "              {\n",
    "                \"Arm GroupLabel\":\"blank control\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: avatrombopag\"\n",
    "                  ]\n",
    "                }\n",
    "              },{\n",
    "                \"Arm GroupLabel\":\"primary prevention\",\n",
    "                \"Arm GroupType\":\"Experimental\",\n",
    "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\\n\\nDrug-withdrawal indications:\\n\\nPLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\\n\\nWhen platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
    "                \"Arm GroupIntervention List\":{\n",
    "                  \"Arm GroupInterventionName\":[\n",
    "                    \"Drug: avatrombopag\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention List\":{\n",
    "            \"Intervention\":[\n",
    "              {\n",
    "                \"InterventionType\":\"Drug\",\n",
    "                \"InterventionName\":\"avatrombopag\",\n",
    "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
    "                \"InterventionArm GroupLabelList\":{\n",
    "                  \"InterventionArm GroupLabel\":[\n",
    "                    \"blank control\",\n",
    "                    \"primary prevention\"\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Outcomes Module\":{\n",
    "          \"Primary Outcome List\":{\n",
    "            \"Primary Outcome\":[\n",
    "              {\n",
    "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
    "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Secondary Outcome List\":{\n",
    "            \"Secondary Outcome\":[\n",
    "              {\n",
    "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
    "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Eligibility Module\":{\n",
    "          \"Eligibility Criteria\":\"Inclusion Criteria:\\n\\nHistologically confirmed lymphoma;\\nPatients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\\nEastern Cooperative Oncology Group (ECOG) of 0-1;\\nProper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\\nAble to use oral drugs\\nPatients volunteer to sign an informed consent\\nLife expectancy > 3 months;\\nContraceptives are used\\n\\nExclusion Criteria:\\n\\nThrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\\nIn addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\\nA thrombosis of a coronary artery or vein developed during three months before screening;\\nHaemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\\nPlatelet transfusion during two days before randomization;\\nAllergic to avatrombopag;\\nParticipation in any other research about novel agents or devices;\\nPregnant or breastfeeding women;\\nResearchers consider it unsuitable for patients to participate in this study.\",\n",
    "          \"Healthy Volunteers\":\"No\",\n",
    "          \"Gender\":\"All\",\n",
    "          \"Minimum Age\":\"18 Years\",\n",
    "          \"MaximumAge\":\"70 Years\",\n",
    "          \"Std Age List\":{\n",
    "            \"Std Age\":[\n",
    "              \"Adult\",\n",
    "              \"Older Adult\"\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Contacts Locations Module\":{\n",
    "          \"CentralContactList\":{\n",
    "            \"CentralContact\":[\n",
    "              {\n",
    "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
    "                \"CentralContactRole\":\"Contact\",\n",
    "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
    "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
    "              },{\n",
    "                \"CentralContactName\":\"Cai\",\n",
    "                \"CentralContactRole\":\"Contact\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Overall Official List\":{\n",
    "            \"Overall Official\":[\n",
    "              {\n",
    "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
    "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
    "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Location List\":{\n",
    "            \"Location\":[\n",
    "              {\n",
    "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
    "                \"LocationCity\":\"Guangzhou\",\n",
    "                \"LocationState\":\"Guangdong\",\n",
    "                \"LocationZip\":\"510060\",\n",
    "                \"LocationCountry\":\"China\",\n",
    "                \"LocationContactList\":{\n",
    "                  \"LocationContact\":[\n",
    "                    {\n",
    "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
    "                      \"LocationContactRole\":\"Contact\"\n",
    "                    }\n",
    "                  ]\n",
    "                }\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      },\n",
    "      \"Derived Section\":{\n",
    "        \"Misc Info Module\":{\n",
    "          \"Version Holder\":\"May 19, 2023\"\n",
    "        },\n",
    "        \"Condition Browse Module\":{\n",
    "          \"Condition Mesh List\":{\n",
    "            \"Condition Mesh\":[\n",
    "              {\n",
    "                \"Condition MeshId\":\"D000008223\",\n",
    "                \"Condition MeshTerm\":\"Lymphoma\"\n",
    "              },{\n",
    "                \"Condition MeshId\":\"D000013921\",\n",
    "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Ancestor List\":{\n",
    "            \"Condition Ancestor\":[\n",
    "              {\n",
    "                \"Condition AncestorId\":\"D000009370\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000009369\",\n",
    "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008232\",\n",
    "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000008206\",\n",
    "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007160\",\n",
    "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000007154\",\n",
    "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000001791\",\n",
    "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
    "              },{\n",
    "                \"Condition AncestorId\":\"D000006402\",\n",
    "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Leaf List\":{\n",
    "            \"Condition Browse Leaf\":[\n",
    "              {\n",
    "                \"Condition Browse LeafId\":\"M10372\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M15832\",\n",
    "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
    "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M11467\",\n",
    "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10377\",\n",
    "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M10355\",\n",
    "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9358\",\n",
    "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M9352\",\n",
    "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M4224\",\n",
    "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"M8642\",\n",
    "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
    "                \"Condition Browse LeafRelevance\":\"low\"\n",
    "              },{\n",
    "                \"Condition Browse LeafId\":\"T3543\",\n",
    "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
    "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
    "                \"Condition Browse LeafRelevance\":\"high\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Condition Browse Branch List\":{\n",
    "            \"Condition Browse Branch\":[\n",
    "              {\n",
    "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
    "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
    "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
    "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"All\",\n",
    "                \"Condition Browse BranchName\":\"All Conditions\"\n",
    "              },{\n",
    "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
    "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        },\n",
    "        \"Intervention Browse Module\":{\n",
    "          \"Intervention Browse Leaf List\":{\n",
    "            \"Intervention Browse Leaf\":[\n",
    "              {\n",
    "                \"Intervention Browse LeafId\":\"M5918\",\n",
    "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
    "                \"Intervention Browse LeafRelevance\":\"low\"\n",
    "              }\n",
    "            ]\n",
    "          },\n",
    "          \"Intervention Browse Branch List\":{\n",
    "            \"Intervention Browse Branch\":[\n",
    "              {\n",
    "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
    "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
    "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
    "              },{\n",
    "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
    "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
    "              }\n",
    "            ]\n",
    "          }\n",
    "        }\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\n",
    "临床专家\n",
    "性别：女\n",
    "首页 /临床科室 /内科系列 /内科 /临床专家\n",
    "蔡清清\n",
    "职务：科副主任\n",
    "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
    "专长\n",
    "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
    " \n",
    "\n",
    " \n",
    "\n",
    "姓名：蔡清清\n",
    "\n",
    " \n",
    "\n",
    "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
    "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
    "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
    "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
    "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
    "加载更多\n",
    "\n",
    "蔡清清的代表性文章、成果：\n",
    "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
    "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
    "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
    "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
    "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
    "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
    "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
    "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
    "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
    "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
    "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
    "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
    "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
    "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
    "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:23.449455Z",
     "start_time": "2023-06-14T06:42:23.433615900Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:42:24,410 - common.py - [line]:28 - INFO - get_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:42:35,570 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:42:35,572 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：蔡清清的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "    临床研究clinical trials，NCT05572983\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":22633,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT05572983\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
      "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"September 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"September 1, 2022\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"September 1, 2024\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"September 1, 2026\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"September 30, 2022\",\n",
      "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"October 10, 2022\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"October 10, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"47\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Chidamide combined with CHOP\",\n",
      "                    \"Drug: Chidamide\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
      "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Induction treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide\",\n",
      "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Maintenance treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
      "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
      "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Age ≥18 years old and ≤75 years old, male and female;\n",
      "Peripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\n",
      "Never received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\n",
      "Autologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\n",
      "There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\n",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\n",
      "Expected survival ≥ 3 months;\n",
      "\n",
      "The following required baseline laboratory data:\n",
      "\n",
      ".White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\n",
      ".Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\n",
      ".Renal function：creatinine, Cr≤1.5×ULN\n",
      ".Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\n",
      ".Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\n",
      "Subjects fully understand and voluntarily participate in this study and sign informed consent\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\n",
      "Patients with significant vital organ dysfunction;\n",
      "Patients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\n",
      "Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\n",
      "Patients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\n",
      "Subjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\n",
      "With active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\n",
      "Patients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\n",
      "Patients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\n",
      "Long-term unhealed wounds or incomplete healing fractures;\n",
      "Receive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\n",
      "Pregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\n",
      "Patients with mental illness or who cannot obtain informed consent;\n",
      "There is active infection, except for tumor-related B symptoms and fever;\n",
      "Cardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n",
      "Ineligibility to participate in the study was determined by the investigator.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Study Director\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510000\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016399\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016411\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008228\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17981\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
      "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17985\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10374\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4496\",\n",
      "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5879\",\n",
      "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M17106\",\n",
      "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M6644\",\n",
      "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M13273\",\n",
      "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M16647\",\n",
      "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M227311\",\n",
      "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
      "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04996758\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":66911,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04996758\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-055\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
      "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"August 1, 2021\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"August 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"August 2028\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"August 5, 2021\",\n",
      "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"August 9, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 24, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Nasopharyngeal Carcinoma\",\n",
      "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"39\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Toripalimab and Anlotinib\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
      "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
      "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
      "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
      "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed undifferentiated non-keratinizing carcinoma\n",
      "Patients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\n",
      "Without other malignancy;\n",
      "Male or female, 18-70 years;\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-2;\n",
      "Life expectancy ≥ 3 months;\n",
      "Women of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\n",
      "At least one evaluable lesion；\n",
      "Laboratory tests meet the following standards:\n",
      "\n",
      "Blood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\n",
      "\n",
      "No serious cardiopulmonary dysfunction;\n",
      "The informed consent has been signed.\n",
      "Ability to comply with test requirements\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A known allergy to any of the drugs in the study;\n",
      "Pregnant or breastfeeding women;\n",
      "Participated in clinical trials of other drugs within 4 weeks prior to study initiation;\n",
      "Previous treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\n",
      "Recurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\n",
      "Palliative radiotherapy for symptom control within 28 days before enrollment;\n",
      "Immunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\n",
      "Active autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\n",
      "A history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\n",
      "Vaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\n",
      "Invasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\n",
      "A history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\n",
      "Abnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\n",
      "Unstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\n",
      "Patients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\n",
      "Patients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\n",
      "A history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\n",
      "Multiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\n",
      "Overoperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\n",
      "Patients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\n",
      "Exacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\n",
      "Active pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\n",
      "Dominant jaundice due to abnormal liver function within 7 days;\n",
      "Renal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\n",
      "Minor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\n",
      "Major surgery within 28 days before enrollment;\n",
      "A potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\n",
      "Long-term unhealed wounds or incomplete fractures;\n",
      "Symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\n",
      "The presence of serious or uncontrolled infections;\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationZip\":\"510030\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"18565617120\",\n",
      "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000002277\",\n",
      "                \"Condition MeshTerm\":\"Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000077274\",\n",
      "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000012008\",\n",
      "                \"Condition MeshTerm\":\"Recurrence\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009375\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000020969\",\n",
      "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010335\",\n",
      "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009303\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010610\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010039\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006258\",\n",
      "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009302\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010608\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009057\",\n",
      "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010038\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M4686\",\n",
      "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M14002\",\n",
      "                \"Condition Browse LeafName\":\"Recurrence\",\n",
      "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M1730\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11472\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M21853\",\n",
      "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11406\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12669\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12114\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8500\",\n",
      "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11405\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12667\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11169\",\n",
      "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12113\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4047\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
      "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
      "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
      "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04797182\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":82232,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04797182\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-034\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
      "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2021\",\n",
      "          \"Overall Status\":\"Not yet recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"April 2021\",\n",
      "            \"Start DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"April 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"July 2023\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"March 11, 2021\",\n",
      "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"March 15, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 15, 2021\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Thrombocytopenia\",\n",
      "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
      "              \"Lymphoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Randomized\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"46\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"blank control\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"primary prevention\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\n",
      "\n",
      "Drug-withdrawal indications:\n",
      "\n",
      "PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\n",
      "\n",
      "When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"avatrombopag\",\n",
      "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"blank control\",\n",
      "                    \"primary prevention\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed lymphoma;\n",
      "Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-1;\n",
      "Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\n",
      "Able to use oral drugs\n",
      "Patients volunteer to sign an informed consent\n",
      "Life expectancy > 3 months;\n",
      "Contraceptives are used\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "Thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\n",
      "In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\n",
      "A thrombosis of a coronary artery or vein developed during three months before screening;\n",
      "Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\n",
      "Platelet transfusion during two days before randomization;\n",
      "Allergic to avatrombopag;\n",
      "Participation in any other research about novel agents or devices;\n",
      "Pregnant or breastfeeding women;\n",
      "Researchers consider it unsuitable for patients to participate in this study.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000013921\",\n",
      "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000001791\",\n",
      "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006402\",\n",
      "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M15832\",\n",
      "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M4224\",\n",
      "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8642\",\n",
      "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5918\",\n",
      "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床专家\n",
      "性别：女\n",
      "首页 /临床科室 /内科系列 /内科 /临床专家\n",
      "蔡清清\n",
      "职务：科副主任\n",
      "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长\n",
      "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "姓名：蔡清清\n",
      "\n",
      " \n",
      "\n",
      "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
      "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
      "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
      "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
      "加载更多\n",
      "\n",
      "蔡清清的代表性文章、成果：\n",
      "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
      "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
      "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
      "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
      "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
      "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
      "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
      "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
      "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
      "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
      "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
      "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
      "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
      "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
      "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：蔡清清的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "    临床研究clinical trials，NCT05572983\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":22633,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT05572983\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"SL-B2022-485-02\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\",\n",
      "          \"Official Title\":\"Phase Ⅱ Study of Chidamide in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype （SWIFT）\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"September 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"September 1, 2022\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"September 1, 2024\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"September 1, 2026\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"September 30, 2022\",\n",
      "          \"Study First Submit QC Date\":\"October 7, 2022\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"October 10, 2022\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"October 7, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"October 10, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This is a prospective, open-label, single arm, multicenter clinical study to evaluate the safety, tolerability, efficacy of chidamide in combination with CHOP in previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"47\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Chidamide in Combination With CHOP\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients with previously untreated peripheral T-cell lymphoma with follicular helper of T cell phenotype will receive chidamide in combination with CHOP for 6 cycles (planned) (21 days per cycle). After 6 cycles of induction therapy, if complete remission (CR) was achieved, maintenance treatment with chidamide will be continued for two years.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Chidamide combined with CHOP\",\n",
      "                    \"Drug: Chidamide\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide combined with CHOP\",\n",
      "                \"InterventionDescription\":\"A)Chidamide: 20mg, D1, 4,8,11, po; B) Cyclophosphamide: 750 mg/ m2, D1, iv.drip; C) Doxorubicin: 50 mg/ m2, D1, iv.drip (or epirubicin 70 mg/ m2, D1, iv.drip); D) Vincristine: 1.4 mg/ m2, D1 (maximum dose 2mg, maximum dose 1.5mg for age over 70 years), iv; E) Prednisone: 40mg/m2, D1-5,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Induction treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Chidamide\",\n",
      "                \"InterventionDescription\":\"Chidamide: 20mg，qw（d1,d4）,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Chidamide in Combination With CHOP\"\n",
      "                  ]\n",
      "                },\n",
      "                \"InterventionOtherNameList\":{\n",
      "                  \"InterventionOtherName\":[\n",
      "                    \"Maintenance treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Complete remission rate\",\n",
      "                \"Primary OutcomeDescription\":\"Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Primary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Objective response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial remission rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Progression-free survival（PFS）\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date of death from any cause, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Recurrence free survival\",\n",
      "                \"Secondary OutcomeDescription\":\"To investigate the preliminary antitumor efficacy\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"From date of randomization until the date ofthe occurrence of relapse or last visit, assessed up to 24 months\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0\",\n",
      "                \"Secondary OutcomeDescription\":\"To identify the incidence of AE and SAE\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"Up to 18 weeks\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Age ≥18 years old and ≤75 years old, male and female;\n",
      "Peripheral T-Cell lymphoma with follicular helper of T cell phenotype confirmed by histopathology at the study center, including: ① Angioimmunoblastic T-cell lymphoma (AITL), ②follicular T-cell lymphoma (FTCL), and ③ other nodal PTCL with TFH phenotype;\n",
      "Never received chemotherapy, radiotherapy, immunological and biological therapy for lymphoma before;\n",
      "Autologous stem cell transplantation is not suitable or the patient refused to accept autologous stem cell transplantation;\n",
      "There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma: measurable lesion: Positron emission tomography / computed tomography (PET/CT) or CT and/or MRI, intranode lesions with long diameter >1.5cm, short diameter >1.0cm, or exnode lesions with long diameter > 1.0 cm; PET CT examination of the lesion showing increased uptake in lymph nodes or extranodal areas (higher than liver) and imaging features consistent with lymphoma can be evaluated.\n",
      "Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2；\n",
      "Expected survival ≥ 3 months;\n",
      "\n",
      "The following required baseline laboratory data:\n",
      "\n",
      ".White blood cell，WBC≥3.0×109/L(Bone marrow invasive patient≥2.0×109/L), Absolute neutrophil count，ANC ≥1.5×109/L, （Bone marrow invasive patient≥1.0×109/L), Platelet count (PLT) ≥75×109/L, （Bone marrow invasive patient≥50×109/L) ，Hemoglobin (HB)≥ 80g/L;\n",
      ".Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN) (The liver invasion ≤3.0×ULN), Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN（The liver invasion≤5.0×ULN）\n",
      ".Renal function：creatinine, Cr≤1.5×ULN\n",
      ".Coagulation function： International Normalized Ratio (INR)≤1.5 ×ULN； Prothrombin Time (PT)、Activated Partial Thromboplastin Time (APTT)≤1.5×ULN（Unless the patient is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time）；\n",
      ".Thyroid stimulating hormone (TSH) or free thyroid hormone (FT4) or free triiodothyronine (FT3) were within 10% of normal value (note: abnormal TSH caused by non-autoimmune causes can be included in the group);\n",
      "Subjects fully understand and voluntarily participate in this study and sign informed consent\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A history of other malignant tumors within the past 5 years; Or other tumors (except basal cell carcinoma of the skin)\n",
      "Patients with significant vital organ dysfunction;\n",
      "Patients with active bleeding or newly developed thrombotic disease, and patients who are taking anticoagulants and having a bleeding tendency;\n",
      "Patients with a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired Immunodeficiency syndrome;\n",
      "Patients with active chronic hepatitis B or active hepatitis C. Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody positive during the screening period require further testing for Hepatitis B Virus (HBV) DNA and HCV RNA. If HBV DNA is no more than 2500 copies /mL or 500 IU/mL and HCV RNA is no more than the lower limit of the assay, enrollment will be allowed after exclusion of treatment-requiring active hepatitis B or C infection. Hepatitis B virus carriers, stable hepatitis B (no more than 2500 copies /mL or 500 IU/mL of DNA) and cured hepatitis C patients were eligible;\n",
      "Subjects who were treated with systemic glucocorticoids or other immunosuppressive agents for a condition within 14 days prior to initiation of study treatment {Local, ocular, intra-articular, intranasal, and inhaled glucocorticoids were allowed (with very low systemic absorption); Short-term (≤ 7 days) use of glucocorticoids for prophylactic treatment (e.g., contrast media allergy) or for treatment of non-autoimmune conditions (e.g., delayed hypersensitivity due to contact allergens) is allowed;\n",
      "With active, and in the past two years need systemic treatment of autoimmune diseases (hormone replacement therapy is not considered a systemic treatment, such as type 1 diabetes, hypothyroidism only requiring thyroid hormone replacement therapy, low adrenocortical or pituitary function only requiring physiological doses of sugar cortical hormone replacement therapy ); Patients with autoimmune diseases that have not required systemic treatment in the past two years are eligible;\n",
      "Patients with unstable angina and/or congestive heart failure or vascular disease (such as, the aortic aneurysm or peripheral venous thrombosis requiring surgery to repair) requiring hospital treatment within 12 months. Patients with other cardiac damage (such as poor control of arrhythmia, myocardial infarction, or ischemic) which may affect the drug safety evaluation within 12 months;\n",
      "Patients who underwent major surgery within 28 days before enrollment; Less than 6 weeks after major organ surgery;\n",
      "Long-term unhealed wounds or incomplete healing fractures;\n",
      "Receive live attenuated vaccine (except influenza vaccine) within 4 weeks before enrollment or during the study period;\n",
      "Pregnant or lactating women and subjects of reproductive age who do not want to take contraceptive measures;\n",
      "Patients with mental illness or who cannot obtain informed consent;\n",
      "There is active infection, except for tumor-related B symptoms and fever;\n",
      "Cardiac clinical symptoms or diseases that are not well controlled, such as: I. Nyha grade 2 or above heart failure; II. Unstable angina pectoris; III. Myocardial infarction has occurred within 1 year; IV. Patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n",
      "Ineligibility to participate in the study was determined by the investigator.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"75 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Study Director\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510000\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016399\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000016411\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma, T-Cell, Peripheral\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008228\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoma, Non-Hodgkin\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17981\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell\",\n",
      "                \"Condition Browse LeafAsFound\":\"T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M17985\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, T-Cell, Peripheral\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10374\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma, Non-Hodgkin\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4496\",\n",
      "                \"Condition Browse LeafName\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Peripheral T-cell Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5879\",\n",
      "                \"Intervention Browse LeafName\":\"Cyclophosphamide\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M17106\",\n",
      "                \"Intervention Browse LeafName\":\"Epirubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M6644\",\n",
      "                \"Intervention Browse LeafName\":\"Doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M13273\",\n",
      "                \"Intervention Browse LeafName\":\"Prednisone\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M16647\",\n",
      "                \"Intervention Browse LeafName\":\"Vincristine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Intervention Browse LeafId\":\"M227311\",\n",
      "                \"Intervention Browse LeafName\":\"Liposomal doxorubicin\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ARhu\",\n",
      "                \"Intervention Browse BranchName\":\"Antirheumatic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infl\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Inflammatory Agents\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04996758\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":66911,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04996758\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-055\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\",\n",
      "          \"Official Title\":\"Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2022\",\n",
      "          \"Overall Status\":\"Recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"August 1, 2021\",\n",
      "            \"Start DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"August 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"August 2028\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"August 5, 2021\",\n",
      "          \"Study First Submit QC Date\":\"August 5, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"August 9, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 23, 2022\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 24, 2022\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of platinum-based chemotherapy\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Nasopharyngeal Carcinoma\",\n",
      "              \"Recurrent or Metastatic Nasopharyngeal Carcinoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"N/A\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Treatment\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"39\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"Toripalimab and Anlotinib Combination Treatment\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: Toripalimab and Anlotinib\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"Toripalimab and Anlotinib\",\n",
      "                \"InterventionDescription\":\"Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"Toripalimab and Anlotinib Combination Treatment\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"Objective Response rate\",\n",
      "                \"Primary OutcomeDescription\":\"Objective Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Primary Outcome Measure\":\"Disease Control rate\",\n",
      "                \"Primary OutcomeDescription\":\"the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"Progression Free Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to the progression of the tumor or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Overall Survival\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the start of treatment to time of death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Complete Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Complete Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Partial Response rate\",\n",
      "                \"Secondary OutcomeDescription\":\"Partial Response rate will be determined on the basis of investigator assessments\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Duration of Response\",\n",
      "                \"Secondary OutcomeDescription\":\"The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              },{\n",
      "                \"Secondary Outcome Measure\":\"Percentage of Participants With Adverse Events\",\n",
      "                \"Secondary OutcomeDescription\":\"Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"5 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed undifferentiated non-keratinizing carcinoma\n",
      "Patients suffered failure of at least one line of platinum-based chemotherapy. The definition of treatment failure: progression during or after chemotherapy for recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months. Withdrawal of treatment due to drug intolerances is excluded ;\n",
      "Without other malignancy;\n",
      "Male or female, 18-70 years;\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-2;\n",
      "Life expectancy ≥ 3 months;\n",
      "Women of childbearing age must obtain the negative result of a pregnancy test (serum or urine) , and they were willing to use reliable methods of contraception during the trial;\n",
      "At least one evaluable lesion；\n",
      "Laboratory tests meet the following standards:\n",
      "\n",
      "Blood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9 /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function: total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine routine: urine protein <2+ ;baseline urine protein ≥2+ and 24 hours urine protein < 1g ; Coagulation: International normalized ratio (INR) and activated partial thrombin time (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)\n",
      "\n",
      "No serious cardiopulmonary dysfunction;\n",
      "The informed consent has been signed.\n",
      "Ability to comply with test requirements\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "A known allergy to any of the drugs in the study;\n",
      "Pregnant or breastfeeding women;\n",
      "Participated in clinical trials of other drugs within 4 weeks prior to study initiation;\n",
      "Previous treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib, fuquinitinib) ;\n",
      "Recurrent nasopharyngeal lesions after radiotherapy and who received secondary radiotherapy;\n",
      "Palliative radiotherapy for symptom control within 28 days before enrollment;\n",
      "Immunosuppressive treatment with immunosuppressive agent, systemic or absorbable topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater than 10mg/ day) within 2 weeks before enrollment;\n",
      "Active autoimmune diseases, with the necessity of systemic treatment (hormone replacement therapy is not considered as a systemic treatment, such as type 1 diabetes) over the past two years; autoimmune diseases that did not require systemic treatment in the past two years;\n",
      "A history of immunodeficiency, including acquired/congenital immunodeficiency disorders, a history of organ transplantation;\n",
      "Vaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is allowed) within 4 weeks before enrollment;\n",
      "Invasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI; tumor with a high risk of affecting vital blood vessels during treatment and causing fatal hemorrhage, which is determined by investigators;\n",
      "A history of severe bleeding and any bleeding event with a severity rating of 3 or higher in the NCI CTCAE within 4 weeks prior to screening;\n",
      "Abnormal coagulation (INR > 2.0, PT > 16s) and bleeding tendency (the INR must be within the normal range without anticoagulants during14 days prior to signing the informed consent); patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily) or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the international normalized ratio of prothrombin time (INR) is ≤ 1.5;\n",
      "Unstable angina and/or congestive heart failure or vascular disease with the need of hospital treatment; other cardiac damage that may affect the drug safety;\n",
      "Patients with hypertension that is not well controlled with antihypertensive medication (systolic > 140mmHg, diastolic > 90 mmHg); patients is taking a combination of two or more antihypertensive drugs; Cardiovascular disease with clinical significance， such as cerebrovascular accident (≤ 6 months before randomization), myocardial infarction (≤ 6 months before randomization), unstable angina, congestive heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on experimental treatments;\n",
      "Patients with esophageal and gastric varices, active ulcers, intestinal perforation or intestinal obstruction within 6 months before enrollment;\n",
      "A history of abdominal fistula, digestive tract perforation, intra-abdominal abscess or acute gastrointestinal bleeding within 6 months before enrollment;\n",
      "Multiple factors affecting oral administration and absorption of drugs (e.g., inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal obstruction);\n",
      "Overoperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous thromboembolism within 6 months before enrollment, such as cerebrovascular accident (including temporary ischemic attack), deep venous thrombosis (except for those venous thrombosis caused by venous catheterization due to previous chemotherapy and determined to be cured by the researchers ), pulmonary embolism, etc.;\n",
      "Patients with past and present objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe impairment of lung function;\n",
      "Exacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory disease requiring hospitalization within 28 days before enrollment;\n",
      "Active pulmonary infection and/or acute bacterial or fungal infection requiring intravenous antibiotic treatment within 28 days;\n",
      "Dominant jaundice due to abnormal liver function within 7 days;\n",
      "Renal insufficiency: routine urinalproteinuria > 2+ and confirmed 24 h urinary protein quantification > 1.0g;\n",
      "Minor surgical operations (including catheterization, excluding central venous catheterization via peripheral venipuncture) within 2 days before enrollment;\n",
      "Major surgery within 28 days before enrollment;\n",
      "A potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4 inducer within two weeks prior to study participation\n",
      "Long-term unhealed wounds or incomplete fractures;\n",
      "Symptomatic central nervous system metastases (e.g. brain edema, need for hormonal intervention, or brain metastases)\n",
      "The presence of serious or uncontrolled infections;\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Qingqing Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University\",\n",
      "                \"LocationStatus\":\"Recruiting\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationZip\":\"510030\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai\",\n",
      "                      \"LocationContactRole\":\"Contact\",\n",
      "                      \"LocationContactPhone\":\"18565617120\",\n",
      "                      \"LocationContactEMail\":\"18565617120@163.com\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000002277\",\n",
      "                \"Condition MeshTerm\":\"Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000077274\",\n",
      "                \"Condition MeshTerm\":\"Nasopharyngeal Carcinoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000012008\",\n",
      "                \"Condition MeshTerm\":\"Recurrence\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009375\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms, Glandular and Epithelial\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000020969\",\n",
      "                \"Condition AncestorTerm\":\"Disease Attributes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010335\",\n",
      "                \"Condition AncestorTerm\":\"Pathologic Processes\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009303\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010610\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010039\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006258\",\n",
      "                \"Condition AncestorTerm\":\"Head and Neck Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009371\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Site\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009302\",\n",
      "                \"Condition AncestorTerm\":\"Nasopharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010608\",\n",
      "                \"Condition AncestorTerm\":\"Pharyngeal Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009057\",\n",
      "                \"Condition AncestorTerm\":\"Stomatognathic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000010038\",\n",
      "                \"Condition AncestorTerm\":\"Otorhinolaryngologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M4686\",\n",
      "                \"Condition Browse LeafName\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M14002\",\n",
      "                \"Condition Browse LeafName\":\"Recurrence\",\n",
      "                \"Condition Browse LeafAsFound\":\"Recurrent\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M1730\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11472\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms, Glandular and Epithelial\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M21853\",\n",
      "                \"Condition Browse LeafName\":\"Disease Attributes\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11406\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12669\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12114\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8500\",\n",
      "                \"Condition Browse LeafName\":\"Head and Neck Neoplasms\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11405\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12667\",\n",
      "                \"Condition Browse LeafName\":\"Pharyngeal Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11169\",\n",
      "                \"Condition Browse LeafName\":\"Stomatognathic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M12113\",\n",
      "                \"Condition Browse LeafName\":\"Otorhinolaryngologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T4047\",\n",
      "                \"Condition Browse LeafName\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Nasopharyngeal Carcinoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC23\",\n",
      "                \"Condition Browse BranchName\":\"Symptoms and General Pathology\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC07\",\n",
      "                \"Condition Browse BranchName\":\"Mouth and Tooth Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC09\",\n",
      "                \"Condition Browse BranchName\":\"Ear, Nose, and Throat Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床研究clinical trials，NCT04797182\n",
      "{\n",
      "  \"Full Study\":{\n",
      "    \"Rank\":82232,\n",
      "    \"Study\":{\n",
      "      \"Protocol Section\":{\n",
      "        \"Identification Module\":{\n",
      "          \"NCT Id\":\"NCT04797182\",\n",
      "          \"Org Study Id Info\":{\n",
      "            \"Org Study Id\":\"B2021-034\"\n",
      "          },\n",
      "          \"Organization\":{\n",
      "            \"Org Full Name\":\"Sun Yat-sen University\",\n",
      "            \"Org Class\":\"OTHER\"\n",
      "          },\n",
      "          \"Brief Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma\",\n",
      "          \"Official Title\":\"Avatrombopag for the Primary Prevention of Thrombocytopenia Induced by Cytarabine-based Chemotherapy in Patients With Lymphoma: An Open, Single-center, Phase II Randomized Controlled Clinical Study\"\n",
      "        },\n",
      "        \"Status Module\":{\n",
      "          \"Status Verified Date\":\"March 2021\",\n",
      "          \"Overall Status\":\"Not yet recruiting\",\n",
      "          \"Expanded Access Info\":{\n",
      "            \"Has Expanded Access\":\"No\"\n",
      "          },\n",
      "          \"Start Date Struct\":{\n",
      "            \"Start Date\":\"April 2021\",\n",
      "            \"Start DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Primary Completion Date Struct\":{\n",
      "            \"Primary Completion Date\":\"April 2023\",\n",
      "            \"Primary Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Completion Date Struct\":{\n",
      "            \"Completion Date\":\"July 2023\",\n",
      "            \"Completion DateType\":\"Anticipated\"\n",
      "          },\n",
      "          \"Study First Submit Date\":\"March 11, 2021\",\n",
      "          \"Study First Submit QC Date\":\"March 11, 2021\",\n",
      "          \"Study First Post Date Struct\":{\n",
      "            \"Study First Post Date\":\"March 15, 2021\",\n",
      "            \"Study First Post DateType\":\"Actual\"\n",
      "          },\n",
      "          \"Last Update Submit Date\":\"March 11, 2021\",\n",
      "          \"Last Update Post Date Struct\":{\n",
      "            \"Last Update Post Date\":\"March 15, 2021\",\n",
      "            \"Last Update Post DateType\":\"Actual\"\n",
      "          }\n",
      "        },\n",
      "        \"Sponsor Collaborators Module\":{\n",
      "          \"Responsible Party\":{\n",
      "            \"Responsible PartyType\":\"Principal Investigator\",\n",
      "            \"Responsible PartyInvestigatorFullName\":\"Qingqing Cai\",\n",
      "            \"Responsible PartyInvestigatorTitle\":\"Chief physician\",\n",
      "            \"Responsible PartyInvestigatorAffiliation\":\"Sun Yat-sen University\"\n",
      "          },\n",
      "          \"Lead Sponsor\":{\n",
      "            \"Lead SponsorName\":\"Sun Yat-sen University\",\n",
      "            \"Lead SponsorClass\":\"OTHER\"\n",
      "          }\n",
      "        },\n",
      "        \"Oversight Module\":{\n",
      "          \"Is FDA Regulated Drug\":\"No\",\n",
      "          \"Is FDA Regulated Device\":\"No\"\n",
      "        },\n",
      "        \"Description Module\":{\n",
      "          \"Brief Summary\":\"This phase 2 trial studies the efficacy and safety of Avatrombopag for the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy in patients with lymphoma\"\n",
      "        },\n",
      "        \"Conditions Module\":{\n",
      "          \"Condition List\":{\n",
      "            \"Condition\":[\n",
      "              \"Thrombocytopenia\",\n",
      "              \"Cytarabine Causing Adverse Effects in Therapeutic Use\",\n",
      "              \"Lymphoma\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Design Module\":{\n",
      "          \"Study Type\":\"Interventional\",\n",
      "          \"PhaseList\":{\n",
      "            \"Phase\":[\n",
      "              \"Phase 2\"\n",
      "            ]\n",
      "          },\n",
      "          \"Design Info\":{\n",
      "            \"DesignAllocation\":\"Randomized\",\n",
      "            \"DesignInterventionModel\":\"Single Group Assignment\",\n",
      "            \"DesignPrimaryPurpose\":\"Prevention\",\n",
      "            \"DesignMaskingInfo\":{\n",
      "              \"DesignMasking\":\"None (Open Label)\"\n",
      "            }\n",
      "          },\n",
      "          \"Enrollment Info\":{\n",
      "            \"Enrollment Count\":\"46\",\n",
      "            \"Enrollment Type\":\"Anticipated\"\n",
      "          }\n",
      "        },\n",
      "        \"Arms Interventions Module\":{\n",
      "          \"Arm Group List\":{\n",
      "            \"Arm Group\":[\n",
      "              {\n",
      "                \"Arm GroupLabel\":\"blank control\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"No intervention aiming at preventing thrombocytopenia will be taken after first cycle. Avatrombopag as salvage treatment will be administered to patients suffering from thrombocytopenia with nadir platelet count < 50 × 109/L at a dose of 60mg/day until there is drug-withdrawal indication.\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              },{\n",
      "                \"Arm GroupLabel\":\"primary prevention\",\n",
      "                \"Arm GroupType\":\"Experimental\",\n",
      "                \"Arm GroupDescription\":\"As the primary prevention of thrombocytopenia induced by cytarabine-based chemotherapy, Avatrombopag will be administered at a dose of 60mg/day on days -3~-1 and 3~9, for a total of 10 doses. On the condition that patients have platelet counts <50 × 10 9 /L before next cycle, Avatrombopag will be administered at a dose of 60mg/day until there is drug-withdrawal indications. Platelet transfusions were administered to patients when the platelet count was less than 10×109 /L.\n",
      "\n",
      "Drug-withdrawal indications:\n",
      "\n",
      "PLT ≥ 100×109/L during salvage treatment or platelet count increases by 50×109/L, comparing with baseline level.\n",
      "\n",
      "When platelet count is higher than 400×109/L during this study, researchers determine whether avatrombopag is discontinued\",\n",
      "                \"Arm GroupIntervention List\":{\n",
      "                  \"Arm GroupInterventionName\":[\n",
      "                    \"Drug: avatrombopag\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention List\":{\n",
      "            \"Intervention\":[\n",
      "              {\n",
      "                \"InterventionType\":\"Drug\",\n",
      "                \"InterventionName\":\"avatrombopag\",\n",
      "                \"InterventionDescription\":\"avatrombopag,60 mg/d,po\",\n",
      "                \"InterventionArm GroupLabelList\":{\n",
      "                  \"InterventionArm GroupLabel\":[\n",
      "                    \"blank control\",\n",
      "                    \"primary prevention\"\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Outcomes Module\":{\n",
      "          \"Primary Outcome List\":{\n",
      "            \"Primary Outcome\":[\n",
      "              {\n",
      "                \"Primary Outcome Measure\":\"The incidence of grades III and IV thrombocytopenia\",\n",
      "                \"Primary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Secondary Outcome List\":{\n",
      "            \"Secondary Outcome\":[\n",
      "              {\n",
      "                \"Secondary Outcome Measure\":\"The durations of any grade thrombocytopenia and grades II, III and IV thrombocytopenia\",\n",
      "                \"Secondary OutcomeTimeFrame\":\"2 years\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Eligibility Module\":{\n",
      "          \"Eligibility Criteria\":\"Inclusion Criteria:\n",
      "\n",
      "Histologically confirmed lymphoma;\n",
      "Patients are scheduled to receive cytarabine-based chemotherapy including Ara-C at dose of 4g/m2.\n",
      "Eastern Cooperative Oncology Group (ECOG) of 0-1;\n",
      "Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.5×10^9/L); platelet count (> 100×10^9/L); Hemoglobin (> 90 g/L); 2) Serum total bilirubin < 1.5 times ULN; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 3 times ULN;3) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 4) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT)< 1.5 times ULN\n",
      "Able to use oral drugs\n",
      "Patients volunteer to sign an informed consent\n",
      "Life expectancy > 3 months;\n",
      "Contraceptives are used\n",
      "\n",
      "Exclusion Criteria:\n",
      "\n",
      "Thrombocytopenia unrelated to chemotherapy during six months before screening, including but not limited to hypersplenism, infection and hemorrhage.\n",
      "In addtion to CIT caused by lymphoma and chemotherapy,patients also suffer from other blood diseases including ALL, AML, myeloid neoplasms, MDS, myeloproliferative disorders, MM;\n",
      "A thrombosis of a coronary artery or vein developed during three months before screening;\n",
      "Haemorrhage with severe clinical symptoms, such as gastrointestinal and cerebral hemorrhage;\n",
      "Platelet transfusion during two days before randomization;\n",
      "Allergic to avatrombopag;\n",
      "Participation in any other research about novel agents or devices;\n",
      "Pregnant or breastfeeding women;\n",
      "Researchers consider it unsuitable for patients to participate in this study.\",\n",
      "          \"Healthy Volunteers\":\"No\",\n",
      "          \"Gender\":\"All\",\n",
      "          \"Minimum Age\":\"18 Years\",\n",
      "          \"MaximumAge\":\"70 Years\",\n",
      "          \"Std Age List\":{\n",
      "            \"Std Age\":[\n",
      "              \"Adult\",\n",
      "              \"Older Adult\"\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Contacts Locations Module\":{\n",
      "          \"CentralContactList\":{\n",
      "            \"CentralContact\":[\n",
      "              {\n",
      "                \"CentralContactName\":\"Qingqing Cai, MD\",\n",
      "                \"CentralContactRole\":\"Contact\",\n",
      "                \"CentralContactPhone\":\"0086-20-87342823\",\n",
      "                \"CentralContactEMail\":\"caiqq@sysucc.org.cn\"\n",
      "              },{\n",
      "                \"CentralContactName\":\"Cai\",\n",
      "                \"CentralContactRole\":\"Contact\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Overall Official List\":{\n",
      "            \"Overall Official\":[\n",
      "              {\n",
      "                \"Overall OfficialName\":\"Qingqing Cai, MD\",\n",
      "                \"Overall OfficialAffiliation\":\"Sun Yat-sen University\",\n",
      "                \"Overall OfficialRole\":\"Principal Investigator\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Location List\":{\n",
      "            \"Location\":[\n",
      "              {\n",
      "                \"LocationFacility\":\"Sun Yat-sen University Cancer Center\",\n",
      "                \"LocationCity\":\"Guangzhou\",\n",
      "                \"LocationState\":\"Guangdong\",\n",
      "                \"LocationZip\":\"510060\",\n",
      "                \"LocationCountry\":\"China\",\n",
      "                \"LocationContactList\":{\n",
      "                  \"LocationContact\":[\n",
      "                    {\n",
      "                      \"LocationContactName\":\"Qingqing Cai, MD\",\n",
      "                      \"LocationContactRole\":\"Contact\"\n",
      "                    }\n",
      "                  ]\n",
      "                }\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      },\n",
      "      \"Derived Section\":{\n",
      "        \"Misc Info Module\":{\n",
      "          \"Version Holder\":\"May 19, 2023\"\n",
      "        },\n",
      "        \"Condition Browse Module\":{\n",
      "          \"Condition Mesh List\":{\n",
      "            \"Condition Mesh\":[\n",
      "              {\n",
      "                \"Condition MeshId\":\"D000008223\",\n",
      "                \"Condition MeshTerm\":\"Lymphoma\"\n",
      "              },{\n",
      "                \"Condition MeshId\":\"D000013921\",\n",
      "                \"Condition MeshTerm\":\"Thrombocytopenia\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Ancestor List\":{\n",
      "            \"Condition Ancestor\":[\n",
      "              {\n",
      "                \"Condition AncestorId\":\"D000009370\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms by Histologic Type\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000009369\",\n",
      "                \"Condition AncestorTerm\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008232\",\n",
      "                \"Condition AncestorTerm\":\"Lymphoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000008206\",\n",
      "                \"Condition AncestorTerm\":\"Lymphatic Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007160\",\n",
      "                \"Condition AncestorTerm\":\"Immunoproliferative Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000007154\",\n",
      "                \"Condition AncestorTerm\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000001791\",\n",
      "                \"Condition AncestorTerm\":\"Blood Platelet Disorders\"\n",
      "              },{\n",
      "                \"Condition AncestorId\":\"D000006402\",\n",
      "                \"Condition AncestorTerm\":\"Hematologic Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Leaf List\":{\n",
      "            \"Condition Browse Leaf\":[\n",
      "              {\n",
      "                \"Condition Browse LeafId\":\"M10372\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M15832\",\n",
      "                \"Condition Browse LeafName\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafAsFound\":\"Thrombocytopenia\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M11467\",\n",
      "                \"Condition Browse LeafName\":\"Neoplasms by Histologic Type\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10377\",\n",
      "                \"Condition Browse LeafName\":\"Lymphoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M10355\",\n",
      "                \"Condition Browse LeafName\":\"Lymphatic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9358\",\n",
      "                \"Condition Browse LeafName\":\"Immunoproliferative Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M9352\",\n",
      "                \"Condition Browse LeafName\":\"Immune System Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M4224\",\n",
      "                \"Condition Browse LeafName\":\"Blood Platelet Disorders\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"M8642\",\n",
      "                \"Condition Browse LeafName\":\"Hematologic Diseases\",\n",
      "                \"Condition Browse LeafRelevance\":\"low\"\n",
      "              },{\n",
      "                \"Condition Browse LeafId\":\"T3543\",\n",
      "                \"Condition Browse LeafName\":\"Lymphosarcoma\",\n",
      "                \"Condition Browse LeafAsFound\":\"Lymphoma\",\n",
      "                \"Condition Browse LeafRelevance\":\"high\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Condition Browse Branch List\":{\n",
      "            \"Condition Browse Branch\":[\n",
      "              {\n",
      "                \"Condition Browse BranchAbbrev\":\"BC04\",\n",
      "                \"Condition Browse BranchName\":\"Neoplasms\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC15\",\n",
      "                \"Condition Browse BranchName\":\"Blood and Lymph Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"BC20\",\n",
      "                \"Condition Browse BranchName\":\"Immune System Diseases\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"All\",\n",
      "                \"Condition Browse BranchName\":\"All Conditions\"\n",
      "              },{\n",
      "                \"Condition Browse BranchAbbrev\":\"Rare\",\n",
      "                \"Condition Browse BranchName\":\"Rare Diseases\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        },\n",
      "        \"Intervention Browse Module\":{\n",
      "          \"Intervention Browse Leaf List\":{\n",
      "            \"Intervention Browse Leaf\":[\n",
      "              {\n",
      "                \"Intervention Browse LeafId\":\"M5918\",\n",
      "                \"Intervention Browse LeafName\":\"Cytarabine\",\n",
      "                \"Intervention Browse LeafRelevance\":\"low\"\n",
      "              }\n",
      "            ]\n",
      "          },\n",
      "          \"Intervention Browse Branch List\":{\n",
      "            \"Intervention Browse Branch\":[\n",
      "              {\n",
      "                \"Intervention Browse BranchAbbrev\":\"Infe\",\n",
      "                \"Intervention Browse BranchName\":\"Anti-Infective Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"ANeo\",\n",
      "                \"Intervention Browse BranchName\":\"Antineoplastic Agents\"\n",
      "              },{\n",
      "                \"Intervention Browse BranchAbbrev\":\"All\",\n",
      "                \"Intervention Browse BranchName\":\"All Drugs and Chemicals\"\n",
      "              }\n",
      "            ]\n",
      "          }\n",
      "        }\n",
      "      }\n",
      "    }\n",
      "  }\n",
      "}\n",
      "\n",
      "临床专家\n",
      "性别：女\n",
      "首页 /临床科室 /内科系列 /内科 /临床专家\n",
      "蔡清清\n",
      "职务：科副主任\n",
      "职称：教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长\n",
      "擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗。\n",
      " \n",
      "\n",
      " \n",
      "\n",
      "姓名：蔡清清\n",
      "\n",
      " \n",
      "\n",
      "职称：内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授\n",
      "专长：主要擅长恶性淋巴瘤和头颈癌（鼻咽癌等）的诊治及恶性肿瘤的造血干细胞移植治疗\n",
      "出诊时间：周一上午特需门诊，周一下午、周四上午专家门诊\n",
      "学术兼职：广东省抗癌协会血液肿瘤专业 委员，秘书；广东省抗癌协会血液肿瘤专业委员会青年委员会副主任委员；中华医学会肿瘤学分会青年委员会副主任委员，广东省女医师协会淋巴瘤专业委员会副主任委员，广东省抗癌协会化疗专业委员会委员，广东省抗癌协会淋巴瘤专业委员会 委员，广州市抗癌协会淋巴瘤专业委员会 常委\n",
      "个人简介：蔡清清教授现任中山大学肿瘤防治中心内科教授，主任医师，博士生导师，淋巴瘤中心主诊教授，中华医学会肿瘤学分会青年委员会副主委，广东省女医师协会淋巴瘤专业委员会副主委，CSCO淋巴瘤联盟专家委员会委员，广东省抗癌协会血液肿瘤专业委员会秘书、委员，广东省抗癌协会血液肿瘤专业委员会青年委员会副主委，广东省抗癌协会淋巴瘤专业委员会委员，广东省抗癌协会化疗专业委员会委员。2013-2014年在美国M.D.Anderson肿瘤中心进修。研究方向淋巴瘤和头颈癌（鼻咽癌），主持多项国家、地方政府及企事业单位项目，其中2项国家自然科学基金面上项目，1项国家自然科学青年基金项目，已在国际著名期刊发表论文40余篇，其中以第一作者和通讯作者发表20余篇，最高影响因子10.199分。培养及正在培养的博士及硕士研究生9名。获第一批广东省杰出青年医学人才，羊城好医生及广东医院最强科室实力中青年医生称号。\n",
      "加载更多\n",
      "\n",
      "蔡清清的代表性文章、成果：\n",
      "1）Cai Q, Tu M, Xu-Monette ZY, Sun R, Manyam GC, Xu X, Tzankov A, Hsi ED, Møller MB, Medeiros LJ, Ok CY, Young KH. NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.5. [Epub ahead of print] （IF=5.485）\n",
      "2）Qian D, Chen K, Deng H, Rao H, Huang H, Liao Y, Sun X, Lu S, Yuan Z, Xie D, Cai Q (corresponding author). MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. Clin Cancer Res. 2015 Jun 22. [Epub ahead of print] （IF=9.6）\n",
      "3）Chen K, Liu Y, Li W, Chen J, Gu Y, Geng Q, Jiang W, Huang H, Lin T, Xia Z, Cai Q (corresponding author). The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2015 Aug;94(8):1389-400. （IF=3.083）\n",
      "4）Cai Q, Luo X, Zhang G, Huang H, Huang H, Lin T, Jiang W, Xia Z, Young KH. New prognostic model for extranodal natural killer/T cell lymphoma, nasal type. Ann Hematol. 2014 Sep;93(9):1541-9. （IF=3.083）\n",
      "5）Cai Q, Luo X, Liang Y, Rao H, Fang X, Jiang W, Lin T, Lin T, Huang H. Fasting blood glucose is a novel prognostic indicator for extranodal natural killer/T-cell lymphoma, nasal type. British Journal of Cancer. 2013,108(2):380-386（IF=5.569）\n",
      "6.）Cai Q, Deng H, Xie D, Lin T, Lin T. Phosphorylated AKT Protein Is Overexpressed in Human Peripheral T-cell Lymphomas and Predicts Decreased Patient Survival. Clin Lymphoma Myeloma Leuk. 2012;12(2):106-12. （IF=2.316）\n",
      "7）Cai Q, Chen K, Chen J, Wu S, Geng Q, Huang H, Lin T, Jiang W, Xia Z, Duan H, Rao H, Yao M, Hu L. The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy. PLoS One. 2016 Oct 6;11(10):e0164210. doi: 10.1371/journal.pone.0164210. eCollection 2016. （IF=3.057）\n",
      "8）Cai Q, Hu L, Geng Q, Chen J, Lu Z, Rao H, Liu Q, Jiang W, Huang H, Lin T, Xia Z. New risk  factors and new tendency for central nervous system relapse in patients with diffuse large  B-cell lymphoma: a retrospective study. Chin J Cancer. 2016 Sep 13;35(1):87. doi:  10.1186/s40880-016-0150-y. （IF=4.111）\n",
      "9）Cai Q, Medeiros LJ, Xu X, Young KH. MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management [Review]. Oncotarget. 2015. （IF=5.008）\n",
      "10）Chen K, Chen J, Rao H, Guo Y, Huang H, Zhang L, Shao J, Lin T, Jiang W, Zou D, Hu L, Wirian M, Cai Q (corresponding author). Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: riskfactors and survival. Chin J Cancer. 2015 May 28;34(5):225-34. （IF=4.111）\n",
      "11）Cai Q, Chen Y, Zou D, Zhang L, Badillo M, Zhou S, Lopez E, Jiang W, HuangH, Lin T, Romaguera J, Wang M. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma. Oncotarget. 2014 Sep 15;5(17):7368-809（IF=5.008）\n",
      "12）Cai Q, Westin J, Fu K, Desai M, Zhang L, Huang H, Jiang W, Liang R, Qian Z, Champlin RE, Wang M. Accelerated therapeutic progress in diffuse large B cell lymphoma [Review]. Ann Hematol. 2014 Apr;93(4):541-56. （IF=3.083）\n",
      "13）Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, LinT. 13-Methyltetradecanoic Acid Exhibits Anti-Tumor Activity on T-Cell Lymphomas In Vitro and In Vivo by Down-Regulating p-AKT and ActivatingCaspase-3.PLoS One. 2013 Jun 7;8(6):e65308.（IF=3.057）\n",
      "14） Huang H, Cai Q (co-first author) , Lin T, Lin X, Liu Y, Gao Y, Peng R.   Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin Pharmacother. 2009;10(15):2399-406. （IF=3.543）\n",
      "15） Cai Q, Huang H, Sun X, Xia Z, Li Y, Lin X, Guo Y. Efficacy and safety of transdermal fentanyl for treatment of oral mucositis pain caused by chemotherapy. Expert Opin Pharmacother. 2008;9(18):3137-44. （IF=3.543）\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7REV3eLC4bXKSYWc5YDsHPdZ1vBli', 'object': 'chat.completion', 'created': 1686724949, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 15664, 'completion_tokens': 203, 'total_tokens': 15867}}\n",
      "2023-06-14 14:42:35,574 - common.py - [line]:40 - INFO - 蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "蔡清清的专长是恶性淋巴瘤（包括非霍奇金淋巴瘤）和头颈癌（如鼻咽癌）的诊治，以及恶性肿瘤的造血干细胞移植治疗。她还对预防白血病细胞钟31的变异具有专长。蔡清清教授在该领域进行了大量的研究，并发表了多篇国内外著名期刊的文章。她还担任多个学术组织的委员和副主任委员，积极参与各种学术活动。\n"
     ]
    }
   ],
   "source": [
    "chat(cqq_txt,\"蔡清清的专长\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:42:35.591497500Z",
     "start_time": "2023-06-14T06:42:24.410407Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "outputs": [],
   "source": [
    "xrh_txt = \"\"\"\n",
    "[\n",
    "  {\n",
    "    \"_id\": \"648019f5778538384fd02da2\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"Ruihua Xu\",\n",
    "    \"hospital\": \"Sun Yat-sen University\",\n",
    "    \"title\": \" MD\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
    "    \"phone\": \"86-20-87343333\",\n",
    "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
    "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": null,\n",
    "    \"awards\": null\n",
    "  },\n",
    "  {\n",
    "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"ruihua Xu\",\n",
    "    \"hospital\": \"Peking University\",\n",
    "    \"title\": \"M.D., Ph.D.\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
    "    \"phone\": \"13922206676\",\n",
    "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
    "    \"brief_intro\": null,\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
    "    \"awards\": null\n",
    "  },\n",
    "  {\n",
    "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
    "    \"avatar\": null,\n",
    "    \"name\": \"Ruihua Xu\",\n",
    "    \"hospital\": \"Sun Yat-sen University\",\n",
    "    \"title\": \"MD\",\n",
    "    \"position\": null,\n",
    "    \"contact\": \"xurh@susycc.org.cn\",\n",
    "    \"phone\": \"+862087343795\",\n",
    "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
    "    \"brief_intro\": null,\n",
    "    \"work_exp\": null,\n",
    "    \"edu_exp\": null,\n",
    "    \"consulting\": null,\n",
    "    \"publications\": null,\n",
    "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
    "    \"awards\": null\n",
    "  }\n",
    "]\n",
    "[\n",
    "  {\n",
    "    \"NCT_No\": \"NCT05830045\",\n",
    "    First_Submitted_Date\": \"April 4, 2023\",\n",
    "    First_Posted_Date\": \"April 26, 2023\",\n",
    "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
    "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"No Changes Posted\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
    "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
    "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
    "    \"Detailed_Description\": \"Not Provided\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: Non-Randomized\\nIntervention Model: Sequential Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Advanced Solid Tumors\",\n",
    "    \"Intervention\": \"Drug: QLP2117\\nSpecified dose on specified days\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
    "    \"Estimated_Enrollment\": \"180\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\\n   8615210162105\\n   meijiang.zhang@qilu-pharma.com\",\n",
    "    \"Listed_Location_Countries\": \"Not Provided\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT05830045\",\n",
    "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\\n   No\",\n",
    "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Xu Ruihua, PhD\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
    "    \"Verification_Date\": \"April 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT05727839\",\n",
    "    First_Submitted_Date\": \"February 1, 2023\",\n",
    "    First_Posted_Date\": \"February 14, 2023\",\n",
    "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
    "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
    "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
    "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
    "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
    "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\\n  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: Non-Randomized\\nIntervention Model: Single Group Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"[List]\",\n",
    "    \"Intervention\": \"Drug: JCXH-211 Injection\\nJCXH-211 administered once every 28 days\\nOther Name: Intratumoral injection\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Recruiting\",\n",
    "    \"Estimated_Enrollment\": \"156\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Qi Wang\\n   +8613381113913\\n   qi.wang@immorna.com\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT05727839\",\n",
    "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Xu ruihua, President\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
    "    \"Verification_Date\": \"March 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT03544905\",\n",
    "    First_Submitted_Date\": \"May 22, 2018\",\n",
    "    First_Posted_Date\": \"June 4, 2018\",\n",
    "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
    "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
    "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
    "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
    "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
    "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\\n  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\\n  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 1\",\n",
    "    \"Study_Design\": \"Allocation: N/A\\nIntervention Model: Single Group Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Advanced Solid Tumors\",\n",
    "    \"Intervention\": \"Drug: CYH33 for tablet\\n1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
    "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\\nTo determine the maximum tolerated dose (MTD) of CYH33\\nIntervention: Drug: CYH33 for tablet\",\n",
    "    \"Publications_*\": \"Not Provided\",\n",
    "    \"Recruitment_Status\": \"Recruiting\",\n",
    "    \"Estimated_Enrollment\": \"100\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact: Ruihua Xu, M.D\\n   86-20-87343804\\n   ruihxu@163.com\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT03544905\",\n",
    "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
    "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   Ruihua Xu, M.D\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
    "    \"Verification_Date\": \"January 2023\"\n",
    "  },\n",
    "  {\n",
    "    \"NCT_No\": \"NCT01198392\",\n",
    "    First_Submitted_Date\": \"September 1, 2010\",\n",
    "    First_Posted_Date\": \"September 10, 2010\",\n",
    "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
    "    Estimated__Study_Start_Date\": \"September 2008\",\n",
    "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
    "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
    "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
    "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
    "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
    "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
    "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
    "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
    "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
    "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
    "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
    "    \"Study_Type\": \"Interventional\",\n",
    "    \"Study_Phase\": \"Phase 3\",\n",
    "    \"Study_Design\": \"Allocation: Randomized\\nIntervention Model: Parallel Assignment\\nMasking: None (Open Label)\\nPrimary Purpose: Treatment\",\n",
    "    \"Condition\": \"Gastric Cancer\",\n",
    "    \"Intervention\": \"[List]\",\n",
    "    \"Study_Arms\": \"[List]\",\n",
    "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
    "    \"Recruitment_Status\": \"Unknown status\",\n",
    "    \"Estimated_Enrollment\": \"270\",\n",
    "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
    "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
    "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
    "    \"Eligibility_Criteria\": \"[List]\",\n",
    "    \"Sex/Gender\": \"Sexes Eligible for Study:\\n   All\",\n",
    "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
    "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
    "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
    "    \"Listed_Location_Countries\": \"China\",\n",
    "    \"Removed_Location_Countries\": null,\n",
    "    \"NCT_Number\": \"NCT01198392\",\n",
    "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
    "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
    "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
    "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
    "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
    "    \"Original_Responsible_Party\": \"Same as current\",\n",
    "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
    "    \"Original_Study_Sponsor\": \"Same as current\",\n",
    "    \"Collaborators\": \"Not Provided\",\n",
    "    \"Investigators\": \"Principal Investigator:\\n   RUIHUA XU, Professor\\n   Sun Yat-sen University\",\n",
    "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
    "    \"Verification_Date\": \"August 2008\"\n",
    "  }\n",
    "]\n",
    "\n",
    "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
    "\n",
    "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
    "\n",
    "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
    "\n",
    "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
    "\n",
    "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
    "\n",
    "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
    "\n",
    "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
    "\n",
    "Representative paper: （*：第一作者，#：通讯作者）\n",
    "\n",
    "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
    "\n",
    "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
    "\n",
    "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
    "\n",
    "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
    "\n",
    "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
    "\n",
    "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
    "\n",
    "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
    "\n",
    "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
    "\n",
    "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
    "\n",
    "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
    "\n",
    "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
    "\n",
    "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
    "\n",
    "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
    "\n",
    "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
    "\n",
    "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
    "\n",
    "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
    "\n",
    "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
    "\n",
    "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
    "\n",
    "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
    "\n",
    "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
    "\n",
    "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
    "\n",
    "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
    "\n",
    "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
    "\n",
    "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
    "\n",
    "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
    "\n",
    "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
    "\n",
    "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
    "\n",
    "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
    "\n",
    "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
    "\n",
    "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
    "\"\"\""
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:20:52.102066100Z",
     "start_time": "2023-06-14T06:20:52.096524400Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:28:37,114 - common.py - [line]:28 - INFO - get_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:28:42,522 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:28:42,522 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:28:42,522 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的专长\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:28:42,522 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7REHgFtmUfUZKTS1rWjy5gziUxjM6', 'object': 'chat.completion', 'created': 1686724120, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '徐瑞华的专长是结直肠癌，pMMR（微卫星稳定性高）型肿瘤和稳定型微卫星的治疗。'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9513, 'completion_tokens': 52, 'total_tokens': 9565}}\n",
      "2023-06-14 14:28:42,532 - common.py - [line]:40 - INFO - 徐瑞华的专长是结直肠癌，pMMR（微卫星稳定性高）型肿瘤和稳定型微卫星的治疗。\n"
     ]
    },
    {
     "data": {
      "text/plain": "'徐瑞华的专长是结直肠癌，pMMR（微卫星稳定性高）型肿瘤和稳定型微卫星的治疗。'"
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的专长\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:28:42.537020500Z",
     "start_time": "2023-06-14T06:28:37.114838600Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:33:41,565 - common.py - [line]:28 - INFO - get_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:33:45,260 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:33:45,260 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:33:45,266 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:33:45,266 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7REMbesgyiRCoJs9vduTyuDZZaugO', 'object': 'chat.completion', 'created': 1686724425, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '{\\n  \"徐瑞华的clinical trial有哪些，列出NCT编号\": [\\n    \"NCT05830045\",\\n    \"NCT05727839\",\\n    \"NCT03544905\",\\n    \"NCT01198392\"\\n  ]\\n}'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 59, 'total_tokens': 9582}}\n",
      "2023-06-14 14:33:45,266 - common.py - [line]:40 - INFO - {\n",
      "  \"徐瑞华的clinical trial有哪些，列出NCT编号\": [\n",
      "    \"NCT05830045\",\n",
      "    \"NCT05727839\",\n",
      "    \"NCT03544905\",\n",
      "    \"NCT01198392\"\n",
      "  ]\n",
      "}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "{\n",
      "  \"徐瑞华的clinical trial有哪些，列出NCT编号\": [\n",
      "    \"NCT05830045\",\n",
      "    \"NCT05727839\",\n",
      "    \"NCT03544905\",\n",
      "    \"NCT01198392\"\n",
      "  ]\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:33:45.286255800Z",
     "start_time": "2023-06-14T06:33:41.565292800Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:33:53,035 - common.py - [line]:28 - INFO - get_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:34:22,230 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:34:22,230 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:34:22,230 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:34:22,230 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7REMmQXAFydoG3FSxsKdjwfeb5OhH', 'object': 'chat.completion', 'created': 1686724436, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '{\\n  \"姓名\": \"徐瑞华\",\\n  \"医院/机构\": [\\n    \"中山大学肿瘤防治中心\"\\n  ],\\n  \"职务\": \"主任、医院院长、研究所所长\",\\n  \"职称\": \"教授、博士生导师\",\\n  \"学术兼职\": [\\n    \"中国医学科学院学部委员\",\\n    \"中国临床肿瘤学会理事长\",\\n    \"中国抗癌协会副理事长\",\\n    \"中国抗癌协会靶向治疗专委会首届主任委员\",\\n    \"中国抗癌协会化疗专委会候任主任委员\",\\n    \"中国临床肿瘤学会肠癌专委会主任委员\"\\n  ],\\n  \"简介\": \"做医学临床及科研工作30多年，取得了突破性的成果。主要从事肠癌的诊治和消化肿瘤免疫治疗研究。发表了很多重要的研究论文，获得了多个科技奖项和荣誉\",\\n  \"邮箱\": [\\n    \"ruihxu@163.com\"\\n  ],\\n  \"手机\": [\\n    \"暂无\"\\n  ],\\n  \"出版著作\": [\\n    \"研究生教材《肿瘤学》主编\",\\n    \"本科生教材《临床肿瘤学》主编\"\\n  ],\\n  \"成就\": [\\n    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\\n    \"连续入选中国高被引学者榜单\",\\n    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\\n    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\\n  ],\\n  \"荣誉获奖\": [\\n    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\\n    \"连续入选中国高被引学者榜单\",\\n    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\\n    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\\n  ],\\n  \"行医\": [\\n    {\\n      \"姓名\": \"徐瑞华\",\\n      \"所属医院/机构\": \"中山大学肿瘤防治中心\",\\n      \"专长\": \"消化肿瘤、肠癌\",\\n      \"临床研究\": [\\n        {\\n          \"研究名称\": \"晚期肠癌的治疗研究\",\\n          \"NCT编号\": \"NCT03544905\"\\n        }\\n      ]\\n    }\\n  ]\\n}'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 943, 'total_tokens': 10466}}\n",
      "2023-06-14 14:34:22,239 - common.py - [line]:40 - INFO - {\n",
      "  \"姓名\": \"徐瑞华\",\n",
      "  \"医院/机构\": [\n",
      "    \"中山大学肿瘤防治中心\"\n",
      "  ],\n",
      "  \"职务\": \"主任、医院院长、研究所所长\",\n",
      "  \"职称\": \"教授、博士生导师\",\n",
      "  \"学术兼职\": [\n",
      "    \"中国医学科学院学部委员\",\n",
      "    \"中国临床肿瘤学会理事长\",\n",
      "    \"中国抗癌协会副理事长\",\n",
      "    \"中国抗癌协会靶向治疗专委会首届主任委员\",\n",
      "    \"中国抗癌协会化疗专委会候任主任委员\",\n",
      "    \"中国临床肿瘤学会肠癌专委会主任委员\"\n",
      "  ],\n",
      "  \"简介\": \"做医学临床及科研工作30多年，取得了突破性的成果。主要从事肠癌的诊治和消化肿瘤免疫治疗研究。发表了很多重要的研究论文，获得了多个科技奖项和荣誉\",\n",
      "  \"邮箱\": [\n",
      "    \"ruihxu@163.com\"\n",
      "  ],\n",
      "  \"手机\": [\n",
      "    \"暂无\"\n",
      "  ],\n",
      "  \"出版著作\": [\n",
      "    \"研究生教材《肿瘤学》主编\",\n",
      "    \"本科生教材《临床肿瘤学》主编\"\n",
      "  ],\n",
      "  \"成就\": [\n",
      "    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\n",
      "    \"连续入选中国高被引学者榜单\",\n",
      "    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\n",
      "    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "  ],\n",
      "  \"荣誉获奖\": [\n",
      "    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\n",
      "    \"连续入选中国高被引学者榜单\",\n",
      "    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\n",
      "    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "  ],\n",
      "  \"行医\": [\n",
      "    {\n",
      "      \"姓名\": \"徐瑞华\",\n",
      "      \"所属医院/机构\": \"中山大学肿瘤防治中心\",\n",
      "      \"专长\": \"消化肿瘤、肠癌\",\n",
      "      \"临床研究\": [\n",
      "        {\n",
      "          \"研究名称\": \"晚期肠癌的治疗研究\",\n",
      "          \"NCT编号\": \"NCT03544905\"\n",
      "        }\n",
      "      ]\n",
      "    }\n",
      "  ]\n",
      "}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "{\n",
      "  \"姓名\": \"徐瑞华\",\n",
      "  \"医院/机构\": [\n",
      "    \"中山大学肿瘤防治中心\"\n",
      "  ],\n",
      "  \"职务\": \"主任、医院院长、研究所所长\",\n",
      "  \"职称\": \"教授、博士生导师\",\n",
      "  \"学术兼职\": [\n",
      "    \"中国医学科学院学部委员\",\n",
      "    \"中国临床肿瘤学会理事长\",\n",
      "    \"中国抗癌协会副理事长\",\n",
      "    \"中国抗癌协会靶向治疗专委会首届主任委员\",\n",
      "    \"中国抗癌协会化疗专委会候任主任委员\",\n",
      "    \"中国临床肿瘤学会肠癌专委会主任委员\"\n",
      "  ],\n",
      "  \"简介\": \"做医学临床及科研工作30多年，取得了突破性的成果。主要从事肠癌的诊治和消化肿瘤免疫治疗研究。发表了很多重要的研究论文，获得了多个科技奖项和荣誉\",\n",
      "  \"邮箱\": [\n",
      "    \"ruihxu@163.com\"\n",
      "  ],\n",
      "  \"手机\": [\n",
      "    \"暂无\"\n",
      "  ],\n",
      "  \"出版著作\": [\n",
      "    \"研究生教材《肿瘤学》主编\",\n",
      "    \"本科生教材《临床肿瘤学》主编\"\n",
      "  ],\n",
      "  \"成就\": [\n",
      "    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\n",
      "    \"连续入选中国高被引学者榜单\",\n",
      "    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\n",
      "    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "  ],\n",
      "  \"荣誉获奖\": [\n",
      "    \"入选科睿唯安（Clarivate Analytics）全球高被引科学家\",\n",
      "    \"连续入选中国高被引学者榜单\",\n",
      "    \"获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖\",\n",
      "    \"入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "  ],\n",
      "  \"行医\": [\n",
      "    {\n",
      "      \"姓名\": \"徐瑞华\",\n",
      "      \"所属医院/机构\": \"中山大学肿瘤防治中心\",\n",
      "      \"专长\": \"消化肿瘤、肠癌\",\n",
      "      \"临床研究\": [\n",
      "        {\n",
      "          \"研究名称\": \"晚期肠癌的治疗研究\",\n",
      "          \"NCT编号\": \"NCT03544905\"\n",
      "        }\n",
      "      ]\n",
      "    }\n",
      "  ]\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:34:22.255303700Z",
     "start_time": "2023-06-14T06:33:53.035822700Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2023-06-14 14:34:54,577 - common.py - [line]:28 - INFO - get_data: model:gpt-3.5-turbo\n",
      "2023-06-14 14:35:09,106 - common.py - [line]:31 - INFO - <Response [200]>\n",
      "2023-06-14 14:35:09,106 - common.py - [line]:32 - INFO - query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "2023-06-14 14:35:09,106 - common.py - [line]:33 - INFO - real_query:\n",
      "    Notice: If doctor or hospital not in the context, skip this one 假如你是数据工程师，请把如下个人信息按照JSON的格式整理给我：（参考字段：行医，门诊时间，综合评价，资质认证状态，基本信息，简介，姓名，医院/机构，专长，职务，职称，学术兼职，地区，邮箱，手机，昕康ID/XK_ID，履历，教育经历，工作经历，研究，研究方向/临床研究，课题/基金，发表，发表文章，出版著作，专利和软著，执笔共识，成就，荣誉获奖）Return only the translation and nothing else:\n",
      "\n",
      "    query:\n",
      "    请根据以下context，回答：徐瑞华的clinical trial有哪些，列出NCT编号\n",
      "    reply in 简体中文\n",
      "    ---------context\n",
      "    \n",
      "[\n",
      "  {\n",
      "    \"_id\": \"648019f5778538384fd02da2\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \" MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xuruihua@sysucc.org.cn\",\n",
      "    \"phone\": \"86-20-87343333\",\n",
      "    \"expertise\": \"Colorectal Carcinoma, pMMR, Microsatellite-stable\",\n",
      "    \"brief_intro\": \"A Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma\",\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": null,\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"64803f25f24b55a336ba235d\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"ruihua Xu\",\n",
      "    \"hospital\": \"Peking University\",\n",
      "    \"title\": \"M.D., Ph.D.\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@mail.sysu.edu.cn\",\n",
      "    \"phone\": \"13922206676\",\n",
      "    \"expertise\": \"nimotuzumab colorectal cancer chemotherapy\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Study of Nimotuzumab to Treat Colorectal Cancer\",\n",
      "    \"awards\": null\n",
      "  },\n",
      "  {\n",
      "    \"_id\": \"6480ea13f24b55a336bec613\",\n",
      "    \"avatar\": null,\n",
      "    \"name\": \"Ruihua Xu\",\n",
      "    \"hospital\": \"Sun Yat-sen University\",\n",
      "    \"title\": \"MD\",\n",
      "    \"position\": null,\n",
      "    \"contact\": \"xurh@susycc.org.cn\",\n",
      "    \"phone\": \"+862087343795\",\n",
      "    \"expertise\": \"Colorectal Cancer,Microsatellite Stable,Chidamide,Sintilimab,PD-1,Bevacizumab\",\n",
      "    \"brief_intro\": null,\n",
      "    \"work_exp\": null,\n",
      "    \"edu_exp\": null,\n",
      "    \"consulting\": null,\n",
      "    \"publications\": null,\n",
      "    \"clinical_res\": \"Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC\",\n",
      "    \"awards\": null\n",
      "  }\n",
      "]\n",
      "[\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05830045\",\n",
      "    First_Submitted_Date\": \"April 4, 2023\",\n",
      "    First_Posted_Date\": \"April 26, 2023\",\n",
      "    Last_Update_Posted_Date\": \"April 26, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"April 20, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"No Changes Posted\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors\",\n",
      "    \"Official_Title\": \"A Study Evaluates the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Advanced Solid Tumor Patients\",\n",
      "    \"Brief_Summary\": \"This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.\",\n",
      "    \"Detailed_Description\": \"Not Provided\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Sequential Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: QLP2117\n",
      "Specified dose on specified days\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Not yet recruiting\",\n",
      "    \"Estimated_Enrollment\": \"180\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 31, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"April 30, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Zhang Meijiang, PhD\n",
      "   8615210162105\n",
      "   meijiang.zhang@qilu-pharma.com\",\n",
      "    \"Listed_Location_Countries\": \"Not Provided\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05830045\",\n",
      "    \"Other_Study_ID_Numbers\": \"QLP2117-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"No\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Plan to Share IPD:\n",
      "   No\",\n",
      "    \"Current_Responsible_Party\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu Ruihua, PhD\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Qilu Pharmaceutical Co., Ltd.\",\n",
      "    \"Verification_Date\": \"April 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT05727839\",\n",
      "    First_Submitted_Date\": \"February 1, 2023\",\n",
      "    First_Posted_Date\": \"February 14, 2023\",\n",
      "    Last_Update_Posted_Date\": \"March 20, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"February 24, 2023\",\n",
      "    Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Primary_Outcome_Measures\": \"[List]\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT05727839 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"[List]\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors\",\n",
      "    \"Official_Title\": \"A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors\",\n",
      "    \"Brief_Summary\": \": A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors\",\n",
      "    \"Detailed_Description\": \"The main purpose of this study is to find out how safe and tolerable the study drug, JCXH-211, is and also how well it works in people with malignant solid tumors. The study drug JCXH-211, is an immunotherapy drug. This means that it aims to work by boosting immune system's response to tumors, to help fight against the growth of the cancer cells. The study has 2 main phases: Phase\n",
      "  1a and Phase 1b. Phase 1a has 2 stages, skin/subcutaneous lesions stage, deep (visceral) lesions stage. Phase 1b will not start until all the data collected in Phase 1a has been completed and reviewed to check that it is safe and well tolerated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: Non-Randomized\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"[List]\",\n",
      "    \"Intervention\": \"Drug: JCXH-211 Injection\n",
      "JCXH-211 administered once every 28 days\n",
      "Other Name: Intratumoral injection\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"156\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"August 24, 2025\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"July 24, 2025   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Qi Wang\n",
      "   +8613381113913\n",
      "   qi.wang@immorna.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT05727839\",\n",
      "    \"Other_Study_ID_Numbers\": \"JCXH-211-003\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Not Provided\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Xu ruihua, President\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Immorna Biotherapeutics, Inc.\",\n",
      "    \"Verification_Date\": \"March 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT03544905\",\n",
      "    First_Submitted_Date\": \"May 22, 2018\",\n",
      "    First_Posted_Date\": \"June 4, 2018\",\n",
      "    Last_Update_Posted_Date\": \"January 6, 2023\",\n",
      "    Estimated__Study_Start_Date\": \"July 5, 2018\",\n",
      "    Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"MTD(Max tolerance does) [ Time Frame: 35 days ]To evaluate the MTD in patients with advanced solid tumor\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT03544905 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Not Provided\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Study to Evaluate the Safety, Tolerate, Pharmacokinetics and Preliminary Efficacy of CYH33\",\n",
      "    \"Official_Title\": \"A Multi-center, Open-label, Single Arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Brief_Summary\": \"This study is a Multi-center, Open-label, single arm, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Advanced Solid Tumors Patients.\",\n",
      "    \"Detailed_Description\": \"This study includes Phase Ia and Phase Ib.\n",
      "  In the dose climbing part of phase Ia, the safety, tolerance and pharmacokinetics characteristics of CYH33 in patients with advanced solid tumors who failed to receive standard treatment, did not tolerate or did not have standard treatment at present will be observed to determine MTD; Before determining MTD, select safe and highly reliable and effective dose levels for simultaneous expansion. Phase Ia dose expansion includes patients with advanced solid tumors who have failed to undergo standard treatment, who are intolerant of PIK3CA gene mutation, or who do not have standard treatment at present, to further evaluate safety, tolerance and initial efficacy.\n",
      "  In Phase Ib, the safety and preliminary efficacy of CYH33 on patients with advanced breast cancer, ovarian cancer, endometrial cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal and gastroesophageal junction squamous cell carcinoma, ovarian clear cell carcinoma and other solid tumors with PIK3CA gene mutation who have failed, are intolerant or do not have standard treatment at present will be evaluated.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 1\",\n",
      "    \"Study_Design\": \"Allocation: N/A\n",
      "Intervention Model: Single Group Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Advanced Solid Tumors\",\n",
      "    \"Intervention\": \"Drug: CYH33 for tablet\n",
      "1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)\",\n",
      "    \"Study_Arms\": \"Experimental: Dose escalation study of CYH33\n",
      "To determine the maximum tolerated dose (MTD) of CYH33\n",
      "Intervention: Drug: CYH33 for tablet\",\n",
      "    \"Publications_*\": \"Not Provided\",\n",
      "    \"Recruitment_Status\": \"Recruiting\",\n",
      "    \"Estimated_Enrollment\": \"100\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"March 31, 2024\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"June 30, 2023   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years and older   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact: Ruihua Xu, M.D\n",
      "   86-20-87343804\n",
      "   ruihxu@163.com\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT03544905\",\n",
      "    \"Other_Study_ID_Numbers\": \"CYH33-101\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"[List]\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   Ruihua Xu, M.D\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Haihe Biopharma Co., Ltd.\",\n",
      "    \"Verification_Date\": \"January 2023\"\n",
      "  },\n",
      "  {\n",
      "    \"NCT_No\": \"NCT01198392\",\n",
      "    First_Submitted_Date\": \"September 1, 2010\",\n",
      "    First_Posted_Date\": \"September 10, 2010\",\n",
      "    Last_Update_Posted_Date\": \"July 25, 2011\",\n",
      "    Estimated__Study_Start_Date\": \"September 2008\",\n",
      "    Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    Current_Primary_Outcome_Measures\": \"Time to progression [ Time Frame: The time from randomization until objective tumor progression or death ]\",\n",
      "    Original_Primary_Outcome_Measures\": \"Same as current\",\n",
      "    Change_History\": \"Complete list of historical versions of study NCT01198392 on ClinicalTrials.gov Archive Site\",\n",
      "    Current_Secondary_Outcome_Measures\": \"Response rate [ Time Frame: 2 months ]\",\n",
      "    Original_Secondary_Outcome_Measures\": \"Same as current\",\n",
      "    Current_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    Original_Other_Pre-specified_Outcome_Measures\": \"Not Provided\",\n",
      "    \"Brief_Title\": \"Trial of S-1 Plus Cisplatin in Gastric Cancer\",\n",
      "    \"Official_Title\": \"A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer\",\n",
      "    \"Brief_Summary\": \"The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced gastric cancer.\",\n",
      "    \"Detailed_Description\": \"This is a randomized, controlled, open-label,multicenter study. Patients are randomized to one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.\",\n",
      "    \"Study_Type\": \"Interventional\",\n",
      "    \"Study_Phase\": \"Phase 3\",\n",
      "    \"Study_Design\": \"Allocation: Randomized\n",
      "Intervention Model: Parallel Assignment\n",
      "Masking: None (Open Label)\n",
      "Primary Purpose: Treatment\",\n",
      "    \"Condition\": \"Gastric Cancer\",\n",
      "    \"Intervention\": \"[List]\",\n",
      "    \"Study_Arms\": \"[List]\",\n",
      "    \"Publications_*\": \"Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, Zhong MZ, Zhang HL, Yu SY, Li W, Hu XH, Wang JJ, Cheng Y, Zhou JT, Guo ZQ, Guan ZG, Xu RH. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget. 2015 Oct 27;6(33):35107-15. doi: 10.18632/oncotarget.5959.\",\n",
      "    \"Recruitment_Status\": \"Unknown status\",\n",
      "    \"Estimated_Enrollment\": \"270\",\n",
      "    \"Original_Estimated_Enrollment\": \"Same as current\",\n",
      "    \"Estimated_Study_Completion_Date\": \"December 2011\",\n",
      "    \"Estimated_Primary_Completion_Date\": \"December 2011   (Final data collection date for primary outcome measure)\",\n",
      "    \"Eligibility_Criteria\": \"[List]\",\n",
      "    \"Sex/Gender\": \"Sexes Eligible for Study:\n",
      "   All\",\n",
      "    \"Ages\": \"18 Years to 75 Years   (Adult, Older Adult)\",\n",
      "    \"Accepts_Healthy_Volunteers\": \"No\",\n",
      "    \"Contacts\": \"Contact information is only displayed when the study is recruiting subjects\",\n",
      "    \"Listed_Location_Countries\": \"China\",\n",
      "    \"Removed_Location_Countries\": null,\n",
      "    \"NCT_Number\": \"NCT01198392\",\n",
      "    \"Other_Study_ID_Numbers\": \"2005L02859\",\n",
      "    \"Has_Data_Monitoring_Committee\": \"Yes\",\n",
      "    \"U.S._FDA-regulated_Product\": \"Not Provided\",\n",
      "    \"IPD_Sharing_Statement\": \"Not Provided\",\n",
      "    \"Current_Responsible_Party\": \"Zhongzhen Guan ,Ruihua Xu, Sun Yat-sen University Cancer Center\",\n",
      "    \"Original_Responsible_Party\": \"Same as current\",\n",
      "    \"Current_Study_Sponsor\": \"Sun Yat-sen University\",\n",
      "    \"Original_Study_Sponsor\": \"Same as current\",\n",
      "    \"Collaborators\": \"Not Provided\",\n",
      "    \"Investigators\": \"Principal Investigator:\n",
      "   RUIHUA XU, Professor\n",
      "   Sun Yat-sen University\",\n",
      "    \"PRS_Account\": \"Sun Yat-sen University\",\n",
      "    \"Verification_Date\": \"August 2008\"\n",
      "  }\n",
      "]\n",
      "\n",
      "徐瑞华，医学博士，中山大学肿瘤防治中心主任、医院院长、研究所所长，华南恶性肿瘤防治全国重点实验室主任，教授，博士生导师。\n",
      "\n",
      "中国医学科学院学部委员，中国临床肿瘤学会理事长，中国抗癌协会副理事长，中国抗癌协会靶向治疗专委会首届主任委员，中国抗癌协会化疗专委会候任主任委员，中国临床肿瘤学会肠癌专委会主任委员，《Cancer Communications》主编，研究生教材《肿瘤学》主编，本科生教材《临床肿瘤学》主编。\n",
      "\n",
      "从事肿瘤内科临床及科研工作30余年，取得突破性成果：\n",
      "\n",
      "第一，实现了肠癌诊治理论和实践的系统创新，使我国肠癌早诊及精准治疗均处于国际先进水平。创新了肠癌早诊及疗效预测的新技术，并已转化为临床应用；建立了晚期肠癌治疗新体系，创建了高效低毒的维持方案和亚洲方案，成为国际治疗新标准，晚期肠癌生存率与国际顶尖的安德森癌症中心达相同水平。\n",
      "\n",
      "第二，创新了消化肿瘤免疫治疗体系，引领国际消化肿瘤免疫治疗发展。\n",
      "\n",
      "通过鉴定TMB、POLE/POLD突变等标志物，精准筛选免疫治疗敏感亚型，大幅提高PD-1抗体疗效；首创了食管癌中国免疫联合方案，取得全球最高有效率72%，已成为食管癌治疗应用最广泛的方案；建立了食管癌EGIC分型，可以指导精准免疫治疗策略，引领该领域的发展；揭示了免疫逃逸新机制并推动了药物的开发：发现甲硫氨酸限制饮食可抑制免疫检查点分子PDL1及VISTA的表达，增强抗肿瘤免疫及抗PD1的治疗效果；鉴定出免疫治疗增效肠道活性菌RX-af01，成果已转化。\n",
      "\n",
      "以通讯或第一作者在国际顶级期刊JAMA、Nature Materials、Nature Medicine、Lancet Oncology等发表SCI论文200余篇，入选科睿唯安（Clarivate Analytics）全球高被引科学家，连续入选中国高被引学者榜单。以第一完成人获国家科技进步二等奖2项及省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖。入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目。\n",
      "\n",
      "Representative paper: （*：第一作者，#：通讯作者）\n",
      "\n",
      "[1]     Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH# ESCORT-1st Investigators.  Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA. 2021 Sep 14;326(10):916-925.\n",
      "\n",
      "[2]     Xu RH*#, Wei W, Krawczyk M, Wang W, Luo H, Flagg K, Yi S, Shi W, Quan Q, Li K, Zheng L, Zhang H, Caughey BA, Zhao Q, Hou J, Zhang R, Xu Y, Cai H, Li G, Hou R, Zhong Z, Lin D, Fu X, Zhu J, Duan Y, Yu M, Ying B, Zhang W, Wang J, Zhang E, Zhang C, Li O, Guo R, Carter H, Zhu JK, Hao X and Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater 2017; 16: 1155-1161.\n",
      "\n",
      "[3]     Xu RH*#, Muro K, Morita S, Iwasa S, Han SW, Wang W, Kotaka M, Nakamura M, Ahn JB, Deng YH, Kato T, Cho SH, Ba Y, Matsuoka H, Lee KW, Zhang T, Yamada Y, Sakamoto J, Park YS and Kim TW. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 2018; 19: 660-671.\n",
      "\n",
      "[4]     Li J, Qin S, Xu R*, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J and Kim TW. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2015; 16: 619-629.\n",
      "\n",
      "[5]     Luo H, Xu G, Li C, He L, Luo L, Wang Z, Jing B, Deng Y, Jin Y, Li Y, Li B, Tan W, He C, Seeruttun SR, Wu Q, Huang J, Huang DW, Chen B, Lin SB, Chen QM, Yuan CM, Chen HX, Pu HY, Zhou F, He Y, Xu RH#. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol. 2019 Oct 4.\n",
      "\n",
      "[6]     Satoh T, Xu RH*, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A and Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014; 32: 2039-2049.\n",
      "\n",
      "[7]     Manish A. Shah, Rui-hua Xu*, Yung-Jue Bang, Paulo M. Hoff, Tianshu Liu, Luis A. Herr´aez-Baranda, Fan Xia,Amit Garg, Mona Shing, and Josep Tabernero. HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology 2017; 35: 2558-2567.\n",
      "\n",
      "[8]     Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH#, Wang F. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cell. 2022 Mar 14;40(3):277-288.\n",
      "\n",
      "[9]     Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH#. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. JAMA Oncol. 2019.\n",
      "\n",
      "[10]   Wang F, Liu DB, Zhao Q, Chen G, Liu XM, Wang YN, Su H, Qin YR, He YF, Zou QF, Liu YH, Lin YE, Liu ZX, Bei JX and Xu RH#. The genomic landscape of small cell carcinoma of the esophagus. Cell Res 2018; 28: 771-774.\n",
      "\n",
      "[11]   Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, Liu Z, Zhao Q, He CY, Lu JH, Wang ZQ, Qiu MZ, Wang F, Wang FH, Li YH, Wang XN, Xie D, Jia WH, Shao YW and Xu RH#. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut 2018;\n",
      "\n",
      "[12]   Feng Wang, You-Sheng Huang, Hao-Xiang Wu, Zi-Xian Wang, Ying Jin, Yi-Chen Yao, Yan-Xing Chen, Qi Zhao, Shifu Chen, Ming-Ming He, Hui-Yan Luo, Miao-Zhen Qiu, De-Shen Wang, Feng-Hua Wang, Mingyan Xu, Yu-Hong Li, Rui-Hua Xu#. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment. Gut. 2022 Jul;71(7):1340-1349.\n",
      "\n",
      "[13]   Luo HY, Li YH, Wang W, Wang ZQ, Yuan X, Ma D, Wang FH, Zhang DS, Lin DR, Lin YC, Jia J, Hu XH, Peng JW and Xu RH#. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Annals of Oncology 2016; 27: 1074-1081.\n",
      "\n",
      "[14]   Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, JF Feng, Y Ba, YP Liu, W Li, YQ Shu, Y Jiang, Q Li, JW Wang, H Wu, H Feng, S Yao, RH Xu#. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019.\n",
      "\n",
      "[15]  Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, Wang W, Sheng H, Pu H, Mo H, Zuo Z, Liu Z, Li C, Xie C, Zeng Z, Li W, Hao X, Liu Y, Cao S, Liu W, Gibson S, Zhang K, Xu G, Xu RH#. Circulating tumor DNA methylation profiles enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Sci Transl Med. 2020 Jan 1;12(524).\n",
      "\n",
      "[16]   Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Dan Xie, Dongxin Lin, Huai-Qiang Ju, Rui-Hua Xu#. METTL3 facilitates tumor progression via an m(6)A-IGF2BP2-dependent mechanism in colorectal carcinoma. Mol Cancer. 2019; 18: 112.\n",
      "\n",
      "[17] Yun Wang, Jia-Huan Lu, Qi-Nian Wu, Ying Jin, De-Shen Wang, Yan-Xing Chen, Jia Liu, Xiao-Jing Luo, Qi Meng, Heng-Ying Pu, Ying-Nan Wang, Pei-Shan Hu, Ze-Xian Liu, Zhao-Lei Zeng, Qi Zhao, Rong Deng, Xiao-Feng Zhu, Huai-Qiang Ju, Rui-Hua Xu#. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Molecular Cancer. 2019 Dec 2.\n",
      "\n",
      "[18]   Jin Y, Chen DL, Wang F, Yang CP, Chen XX, You JQ, Huang JS, Shao Y, Zhu DQ, Ouyang YM, Luo HY, Wang ZQ, Wang FH, Li YH, Xu RH#, Zhang DS. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors. Mol Cancer. 2020 Oct 30;19(1):154.\n",
      "\n",
      "[19]   Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, Huang P, Li YH and Xu RH#. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60: 598-609.\n",
      "\n",
      "[20]   Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ and Xu RH#. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-kappaB activation. Journal of Pineal Research 2016; 60: 27-38.\n",
      "\n",
      "[21]   Ju HQ, Lin JF, Tian T, Xie D, Xu RH#. NADPH homeostasis in cancer: functions, mechanisms and therapeutic implications. Signal Transduct Tar. 2020 Oct 7;5(1):231.\n",
      "\n",
      "[22]  Hu PS, Li T, Lin JF, Qiu MZ, Wang DS, Liu ZX, Chen ZH, Yang LP, Zhang XL, Zhao Q, Chen YX, Lu YX, Wu QN, Pu HY, Zeng ZL, Xie D, Ju HQ, Luo HY, Xu RH#. VDR-SOX2 signaling promotes colorectal cancer stemness and malignancy in an acidic microenvironment. Signal Transduct Tar. 2020 Sep 9;5(1):183.\n",
      "\n",
      "[23]   Ju HQ, Ying H, Tian T, Ling J, Fu J, Lu Y, Wu M, Yang L, Achreja A, Chen G, Zhuang Z, Wang H, Nagrath D, Yao J, Hung MC, DePinho RA, Huang P, Xu RH# and Chiao PJ. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nat Commun 2017; 8: 14437.\n",
      "\n",
      "[24]   Liu J, Liu ZX, Wu QN, Lu YX, Wong CW, Miao L, Wang Y, Wang Z, Jin Y, He MM, Ren C, Wang DS, Chen DL, Pu HY, Feng L, Li B, Xie D, Zeng MS, Huang P, Lin A, Lin D, Xu RH#, Ju HQ. Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming. Nat Commun. 2020 Mar 20;11(1):1507.\n",
      "\n",
      "[25]   Ju HQ, Lu YX, Chen DL, Zuo ZX, Liu ZX, Wu QN, Mo HY, Wang ZX, Wang DS, Pu HY, Zeng ZL, Li B, Xie D, Huang P, Hung MC, Chiao PJ and Xu RH#. Modulation of Redox Homeostasis by Inhibition of MTHFD2 in Colorectal Cancer: Mechanisms and Therapeutic Implications. J Natl Cancer Inst 2018\n",
      "\n",
      "[26] Yu K, Zhang Q, Liu Z, Zhao Q, Zhang X, Wang Y, Wang ZX, Jin Y, Li X, Liu ZX and Xu RH#. qPhos: a database of protein phosphorylation dynamics in humans. Nucleic Acids Res 2018\n",
      "\n",
      "[27] Rui-Hua Xu*, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua & Weiguo Su. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. (2017) 10:22.\n",
      "\n",
      "[28] Gong Chen, Junjie Peng, Qian Xiao, Hao-Xiang Wu, Xiaojun Wu, Fulong Wang, Liren Li, Peirong Ding, Qi Zhao, Yaqi Li, Da Wang, Yang Shao, Hua Bao, Zhizhong Pan, Ke-Feng Ding, Sanjun Cai, Feng Wang, Rui-Hua Xu#. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology & Oncology. 2021 May 17;14(1):80.\n",
      "\n",
      "[29] Zeng ZL, Luo HY, Yang J, Wu WJ, Chen DL, Huang P and Xu RH#. Overexpression of the circadian clock gene Bmal1 increases sensitivity to oxaliplatin in colorectal cancer. Clinical Cancer Research 2014; 20: 1042-1052.\n",
      "\n",
      "[30] Huiyan Luo, Wei Wei, Ziyi Ye, Jiabo Zheng, Rui-hua Xu#. Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA. Trends in Molecular Medicine. 23 Jan 2021.\n",
      "\n",
      "    ---------\n",
      "\n",
      "\n",
      "2023-06-14 14:35:09,106 - common.py - [line]:37 - INFO - json_dict:{'id': 'chatcmpl-7RENlsA2toRyEFU5tnml0OeHgfJmh', 'object': 'chat.completion', 'created': 1686724497, 'model': 'gpt-3.5-turbo-16k-0613', 'choices': [{'index': 0, 'message': {'role': 'assistant', 'content': '{\\n  \"姓名\": \"徐瑞华\",\\n  \"医院/机构\": \"中山大学\",\\n  \"职务\": \"肿瘤防治中心主任、医院院长、研究所所长\",\\n  \"职称\": \"教授、博士生导师\",\\n  \"地区\": \"中国\",\\n  \"邮箱\": \"xuruihua@sysucc.org.cn\",\\n  \"手机\": \"86-20-87343333\",\\n  \"履历\": \"从事肿瘤内科临床及科研工作30余年\",\\n  \"教育经历\": \"医学博士\",\\n  \"工作经历\": \"中山大学肿瘤防治中心主任、医院院长、研究所所长\",\\n  \"研究\": \"肠癌诊治理论和实践的系统创新、消化肿瘤免疫治疗体系\",\\n  \"研究方向/临床研究\": \"肿瘤学、肠癌、消化肿瘤免疫治疗\",\\n  \"发表\": \"SCI论文200余篇\",\\n  \"发表文章\": \"JAMA、Nature Materials、Nature Medicine、Lancet Oncology等\",\\n  \"执笔共识\": \"《Cancer Communications》主编、研究生教材《肿瘤学》主编、本科生教材《临床肿瘤学》主编\",\\n  \"成就\": \"国家科技进步二等奖2项、省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖、入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\\n}'}, 'finish_reason': 'stop'}], 'usage': {'prompt_tokens': 9523, 'completion_tokens': 540, 'total_tokens': 10063}}\n",
      "2023-06-14 14:35:09,111 - common.py - [line]:40 - INFO - {\n",
      "  \"姓名\": \"徐瑞华\",\n",
      "  \"医院/机构\": \"中山大学\",\n",
      "  \"职务\": \"肿瘤防治中心主任、医院院长、研究所所长\",\n",
      "  \"职称\": \"教授、博士生导师\",\n",
      "  \"地区\": \"中国\",\n",
      "  \"邮箱\": \"xuruihua@sysucc.org.cn\",\n",
      "  \"手机\": \"86-20-87343333\",\n",
      "  \"履历\": \"从事肿瘤内科临床及科研工作30余年\",\n",
      "  \"教育经历\": \"医学博士\",\n",
      "  \"工作经历\": \"中山大学肿瘤防治中心主任、医院院长、研究所所长\",\n",
      "  \"研究\": \"肠癌诊治理论和实践的系统创新、消化肿瘤免疫治疗体系\",\n",
      "  \"研究方向/临床研究\": \"肿瘤学、肠癌、消化肿瘤免疫治疗\",\n",
      "  \"发表\": \"SCI论文200余篇\",\n",
      "  \"发表文章\": \"JAMA、Nature Materials、Nature Medicine、Lancet Oncology等\",\n",
      "  \"执笔共识\": \"《Cancer Communications》主编、研究生教材《肿瘤学》主编、本科生教材《临床肿瘤学》主编\",\n",
      "  \"成就\": \"国家科技进步二等奖2项、省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖、入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "+++++++++++++++++++++++++\n",
      "{\n",
      "  \"姓名\": \"徐瑞华\",\n",
      "  \"医院/机构\": \"中山大学\",\n",
      "  \"职务\": \"肿瘤防治中心主任、医院院长、研究所所长\",\n",
      "  \"职称\": \"教授、博士生导师\",\n",
      "  \"地区\": \"中国\",\n",
      "  \"邮箱\": \"xuruihua@sysucc.org.cn\",\n",
      "  \"手机\": \"86-20-87343333\",\n",
      "  \"履历\": \"从事肿瘤内科临床及科研工作30余年\",\n",
      "  \"教育经历\": \"医学博士\",\n",
      "  \"工作经历\": \"中山大学肿瘤防治中心主任、医院院长、研究所所长\",\n",
      "  \"研究\": \"肠癌诊治理论和实践的系统创新、消化肿瘤免疫治疗体系\",\n",
      "  \"研究方向/临床研究\": \"肿瘤学、肠癌、消化肿瘤免疫治疗\",\n",
      "  \"发表\": \"SCI论文200余篇\",\n",
      "  \"发表文章\": \"JAMA、Nature Materials、Nature Medicine、Lancet Oncology等\",\n",
      "  \"执笔共识\": \"《Cancer Communications》主编、研究生教材《肿瘤学》主编、本科生教材《临床肿瘤学》主编\",\n",
      "  \"成就\": \"国家科技进步二等奖2项、省部级一等奖6项、吴阶平医药创新奖、谈家桢临床医学奖及CSCO年度成就奖、入选国家百千万人才工程、全国先进工作者、南粤百杰人才培养工程、国家卫生计生突出贡献中青年专家等人才项目\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "chat(xrh_txt,\"徐瑞华的clinical trial有哪些，列出NCT编号\")"
   ],
   "metadata": {
    "collapsed": false,
    "ExecuteTime": {
     "end_time": "2023-06-14T06:35:09.128636100Z",
     "start_time": "2023-06-14T06:34:54.581225300Z"
    }
   }
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "outputs": [],
   "source": [],
   "metadata": {
    "collapsed": false
   }
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.6"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
